AUSTRIAEXPORT No

AUSTRIAEXPORT No. 116 SPRING 2006 EDITED BY THE AUSTRIAN FEDERAL ECONOMIC CHAMBER, AUSTRIAN TRADE

Biotech & more

1/2005111/2005 www.austriantrade.orgwww.austriantrade.orgaustriantrade.org AUSTRIANTRADE.ORG1 AUSTRIAEXPORT

Biotech & more

3 EDITORIAL

4 ENORMOUS POTENTIAL FOR INNOVATIONS

6 AUSTRIA: A PROFITABLE LOCATION

8 BIOTECH MADE IN AUSTRIA

16 AUSTRIAN COMPANIES FOR PHARMACEUTICALS

21 AUSTRIAN COMPANIES FOR DIAGNOSTICS

23 AUSTRIAN COMPANIES FOR RESEARCH AND DEVELOPMENT

33 AUSTRIAN COMPANIES FOR BIOPROCESSING

35 SUPPLIERS

38 LISTING

41 INDEX

42 AUSTRIAN TRADE COMMISSIONS ABROAD

Published: according to § 25 Law governing Media: Editor: Austrian Federal Economic Chamber, AUSTRIAN TRADE, A-1045 Vienna, Wiedner Hauptstraße 63, T. +43/590 900-4822 • Publishing house: New Business Verlag GmbH, A-1060 Vienna, Magdalenenstraße 33, T. +43/1/2351366-0, F. +43/1/2351366-999 • Concept, editorial and production: PG The Corporate Publishing Group GmbH (CPG) • Chief coordina- tor: Oliver Olbrich (ext. 666) • Marketing editor: Lorin Polak (ext. 300) • Senior editor: Paul Christian Jezek (ext. 400) • Editors: Beyana Maghakian ([email protected]) and Martin Spatz ([email protected]), both Austria Wirtschaftsservice GMBH, LISA • Promotions editor: Gudrun Just • Graphic concept: Gerald Fröhlich (CPG) • Coordinating manager: Gesa Weitzenböck (+43/1/4054640-763) • Cover photo: Archiv AWO • Proofreading: Steve

Wilder • Print: AMG MediengmbH, A-1140 Vienna © Archiv AWO

2 austriantrade.org 116/2006 AUSTRIAEXPORT

Paul Christian Jezek Senior Editor

Biotechnology and Life Sciences Key Technologies in Austria

n the 21st century, biotechnology will be one of the most good example being the research and commercialisation of important technologies of all, as it exercises an enormous new medicines. While biotechnology was understood as the Iamount of influence on broad sections of society and manufacture of genetically engineered agents in medicine a offers solutions for a wide range of applications. few years ago, the field now includes clinical tests, practical Through the development of innovative medical pro- applications, accompanying diagnostics, medical technology ducts, therapies and diagnostic means, it also directly affects and even sales of essential biotechnological components. the making of health policy in general. Thanks to new For this reason, the opportunities with regard to deve- opportunities relating to biotechnology in the field of food lopment and added value in the biosciences in Austria have and nutrition, it also influences general prosperity and qua- not yet been fully exploited, and they go beyond the lity of life considerably, in addition to making important borders separating disciplines. Real progress is normally contributions toward the creation of an ecological society. achieved through a transdisciplinary approach: networking The biotech sector in Austria now encompasses more than of specialised knowledge from the fields of biology, micro- 10,000 employees, the majority in the field of human medi- biology, molecular biology, chemistry, and engineering and cine, and it has a turnover of two billion euros per year. The material sciences is decisive for a great many solutions. At general attitude toward "red” biotechnology and products present, technological progress in the relevant disciplines created with the aid of medical research is extremely positi- takes place in parallel within separate methodological sys- ve. Attitudes are also improving toward "grey” biotechnolo- tems. In other words, lateral communication among various gy, which deals with the environment. Applications in indus- areas is decisive for innovation. trial production processes (e.g. food additives such as citric For the purpose of realising this potential in Austria, acid, which is also used for decalcification; detergents; enzy- expanded networking activities, intensified interdisciplinary mes, e.g. for blood and grass stains; thickeners, such as xan- and cross-sector research, and "translational” research as than gum; bioplastics; and pharmaceutical products and well are all being encouraged. In addition to its direct work intermediates) represent Austrian activities in the field of force requirements, biotechnology generates and ensures "white biotechnology.” Biofuels (biodiesel, ethanol) are additional jobs in related fields, especially the chemical and another prospective field being currently developed. The pharmaceutical industries. On the other hand, the mere acceptance of gentle "green” plant biotechnology is still number of jobs is less important than the fact that they being worked on. require a high level of qualification and are accompanied by In contrast to other groundbreaking technologies, prac- considerable economic value. The great significance bio- tical applications are found over the long term. Lead times science has for pharmaceutical research and development between idea and concrete effect sometimes amount to means that biotechnology and the pharmaceuticals industry several years and can result in considerable expense, one will increasingly cooperate in equal partnerships. ❚

116/2006 austriantrade.org 3 AUSTRIAEXPORT

First-rate research is performed at Boehringer-Ingelheim Austria. © Boehringer-Ingelheim Austria © Boehringer-Ingelheim

Enormous potential for innovations

Austrian biotech companies can look back on an outstanding long tradition and at present make up a dynamically growing scene with such well-known members as Austrianova, igeneon, Intercell, Oridis and Sanochemia.

oreign companies and investors are interested in the Boehringer-Ingelheim Austria, located in Vienna, is the gems in Austria’s biotech crown, one good example centre of oncological research and development, at the same Fbeing the 7.5 million dollars of financing provided to time representing one of the two centres for biopharmaceu- Vienna’s Fibrex Medical Research & Development GmbH by tical production, in the international Boehringer-Ingelheim Global Life Science Ventures, Atlas Venture, EMBL Ventures Group. Two block busters currently being marketed are: the and Mulligan BioCapital AG. active ingredients Interferon gamma and tumour necrosis In addition to flows of international capital, the acquisi- factor alpha. Apart from the investments being made in new tion of domestic cancer-research company igeneon by infrastructure, Boehringer-Ingelheim outlays approximately Aphton of the USA is also typical of the current activity. 60 million euros annually for R&D in Austria. The latest Biotechnology firms located in Austria spend up to one- innovation is a new kind of biofermenter for high cell-densi- half billion euros on research each year. At present, vaccines ty fermentation of bacteria and yeasts. and therapeutic proteins, antibiotics and antiinfectives, And there’s more: Boehringer also runs the Research medicines to treat cancer, non-steroid medications for neu- Institute for Molecular Pathology (IMP), which was founded rodermatitis, DNA chips, "recombinant” allergenics, virus in 1988. The most important institute in Austria that works and prion activation, gene-transport systems and biochips with molecular biology performs research on a variety of for diagnostic purposes are being studied, with some pro- subjects, such as the development of cancer cells, and it has ducts already on the market. earned an excellent reputation among international experts Baxter AG, one of the country’s largest and fastest-gro- in the field. Its neighbour, the Institute of Molecular wing biotech companies, develops and manufactures medici- Biotechnology (IMBA), is operated in close cooperation, and nes, in particular vaccines and therapeutic proteins. the Gregor Mendel Institute for Molecular Plant Biology

4 austriantrade.org 116/2006 AUSTRIAEXPORT

(GMI) is located in the same building. These two institutes, which belong to the Austrian Academy of Sciences perform basic research. Sandoz GmbH (formerly Biochemie GmbH and a member of the Novartis Group), with development and manufacturing operations in Kundl and Schaftenau, has 2,600 employees and is the leading company for pharmaceuticals and generics in Austria. No less than 98% of its sales are made through exports to more than 120 countries. Enzymes, hor- mones and therapeutic proteins are manufactured in Kundl. On January 31, 2006, Nabriva Therapeutics Forschungs GmbH, a biotechnology firm which focuses on antibiotics, opened its doors. This company is a spin-off of Vienna’s © Intercell Antibiotic Research Institute (ABRI), part of the research department of Sandoz GmbH, Kundl. Igeneon – a Novartis spin-off created as one of Austria’s Nabriva concentrates on developing antibiotics for hospi- first biotechnology companies to work on cancer-immunity tal-acquired infections and has an extremely solid pipeline of treatment – develops vaccines designed to prevent or delay antibacterial active agents. At present, three projects are at an the formation of metastases. advanced preclinical stage, and one product will soon be in Austrianova, located at Vienna’s University of Veterinary clinical phase 1. Medicine, is an international pioneer in the research, deve- The Campus Vienna Biocenter (VBC) is the product of a lopment and use of viral gene-transport systems. A method smoothly functioning symbiosis of the private sector and for treating pancreatic cancer is the first and only in Austria both university and non-university research institutes. to be registered as an "orphan medicinal product” by the The Intercell company, founded in 1998 and now listed European Medicines Agency (EMEA). Late in 2005, on the stock exchange, is located at the Campus Vienna Austrianova received credit guarantees totalling 3.5 million Biocenter. Vaccines used to treat diseases such as tuberculo- euros from the Austria Wirtschaftsservice bank to begin mass sis are developed here. Late in 2005, its partner Merck & Co., production of NovaCaps, capsules containing genetically Inc. provided 833,000 euros in recognition of "significant modified living cells which could be on the market by 2008. progress.” The international market launch of a new vaccine Lambda GmbH of Upper Austria develops and manufac- against Japanese encephalitis is planned for 2007, and late in tures biochips for diagnostic applications in addition to wor- 2005, Pelias AG was established as part of a major partners- king with bioanalysis and various kinds of DNA analysis. The hip of Intercell and Parteurop, a renowned consultancy in the company also provides DNA sequencing and validation of field of life sciences. Thanks to financial support provided by test methods in the form of commissioned research. partners around the world and the licensed projects of In close cooperation with Graz’s Technical University, Chiron and Intercell, Pelias intends to develop new kinds of Molekulare Biotechnologie GmbH offers technological vaccines and treatments based on antibodies. Its most impor- expertise relating to genetically engineered production of tant product is a vaccine against pseudomonas infections, enzymes with the Pichia pastoris fungus system. and this medication’s effectiveness has been proven in initi- Also noteworthy are biotechnological products, which are al clinical studies. sold primarily for the manufacture of nutritional supple- Another success at the Biocenter is VBC-Genomics ments. For example, Austria’s Jungbunzlauer is one of the Bioscience Research GmbH, which turns patented biochip world’s most important producers of citric acid. Another item expertise into marketable products for diagnosing allergies in made for the food industry is the thickener xanthan gum. connection with hormone-replacement therapy. Biomay AG The fact that agricultural biotechnology in Austria has to has entered into long-term collaboration with leading allergy deal with difficult terrain is reflected by the number and researchers at the medical universities of Vienna and Salzburg nature of the country’s companies. Solely Maize Techno- to develop new strategies for diagnosing and treating aller- logies International concentrates on crops. gies, especially with "recombinant” allergens, i.e. those which Numerous other firms develop projects in the field of bio- have been produced through genetic engineering. technology, and they now occupy a firm position in the sec- Hämosan develops methods relating to the activation of tor. Included are C4 Holding, Fischer Biotechnology viruses and prions in addition to tests and microbiological Consulting and HL Bioscience. Some other newly founded examinations for veterinary medicine and the production of companies are Greenhills Biotechnology, Onepharm, Eucodis hypericin. and Biodevelops. The Novartis Institutes for BioMedical Research Austria, In 2001, Austria’s biotech firms joined to form Austrian Vienna (NIBR) has been one of the most important centres in Biotech Industry (ABI), which is part of the Association of the Austria for pharmaceutical research since 1970; at present, as Austrian Chemical Industry (FCIO). Both established compa- a centre of excellence for dermatology, it performs research nies and biotechnology start-ups, most of which are active in on innovative treatments for inflammatory skin conditions biopharma, comprise its membership. The ABI maintains (including neurodermatitis) and related allergies and immu- close connections to European and international biotechno- nodeficiencies for the Novartis group. logy networks. http://www.biotechindustry.at ❚

116/2006 austriantrade.org 5 AUSTRIAEXPORT

Austria: a proﬁtable location

The ideal hub for Central and Eastern Europe: Austria’s attractive business environment offers political and social stability, close connections to the growth markets of Eastern Europe, superb education and training for Austria’s workforce and a number of competitive tax advantages for companies operating in Austria. Martin Spatz

ustria’s geographical location provides ideal access to extensive knowledge of Eastern Europe: for example, banks, the emerging markets of Central and Eastern Europe, management consultants and tax advisors have established Awhich amount to almost 450 million people. wide-ranging contacts and gained a profound understanding Vienna’s Schwechat Airport offers the highest number of of East-West business, knowing exactly "who, how and with direct flights into the new EU member states, and excellent whom”. Leading companies from across the business spec- motorway and railway systems have been established. trum are choosing Austria as their support base for Central Furthermore, the Danube links Austria with Slovakia, and Eastern Europe: for example, global companies such as Hungary, Croatia, Serbia and Montenegro, Romania, Boehringer, BASF, Bayer, Baxter, Beiersdorf, Siemens, Bulgaria, Moldova and Ukraine. In contrast to Western Henkel, Degussa-Hüls and Eli Lilly have already established Europe’s saturated markets, the nations of Eastern Europe their Eastern European headquarters in Vienna. offer enormous opportunities, with up to 6% growth fore- There is much to learn about Austria as a business loca- cast in the coming years. The unanimous opinion of econo- tion. General information and support can be obtained from mic experts is that Austria will benefit more than any other the Austrian Business Agency (www.aba.gv.at). EU member from the most recent enlargement, thanks to its longstanding commercial ties to new member states. Most Low taxes important of all, however, is Austrian service providers’ The reduction of the corporate income tax rate to 25% in 2005 elevated Austria to a top position among Europe’s most business-friendly nations. Among the EU-15, only Ireland offers more favourable tax provisions. However, Austria also makes a strong showing in compa- rison to the new EU member states that are attracting investors through major tax reductions. According to calculations done by the Vienna Institute for Advanced Studies, Austria’s tax reform will reduce the effective corporate tax rate even further, to 22%. This advantage is attributable to numerous write-offs, including a research premium of 8%. Research and training exemptions, deductions for losses and the car- ryover of silent reserves are also resulting in significant reductions. Companies will benefit from the group taxation relief: under the new provisions, the profits and losses of domestic group members are offset along with the losses of foreign subsidiaries, which reduces the basis for calculation of the corporate tax. Up to 35% of research expenditures are excludable if applied to the development or improvement of inventions with macroeconomic value. Investments in the form of silent partnerships enjoy tax advantages under Austrian law and also play an important indirect role in subsidising and financing commercial research and development. Taken together, Austria has an these provisions make Austria’s tax system the most attracti- enormous amount of ve in Europe with regard to research and development. potential in the life- sciences sector. Investing in biotech

Outstanding research facilities and the presence of international pharmaceutical companies provide the framework for © WWFF Austria’s thriving biotechnology scene. Support and assis-

6 austriantrade.org 116/2006 AUSTRIAEXPORT

The biotech sector in Austria now encompasses more than 10,000 employees, the majority in the field of human medicine, and it has turnover of two billion euros per year. © WWFF tance is provided to biotech companies primarily by the Largest VC Funding Rounds in Austria federal Life Science Austria (LISA) programme and regional initiatives. LISA draws on many years of experience in the 29 mil. euros: Intercell AG, Vienna, January 2001 life sciences to put this expertise at the disposal of potential Global Life Sciences Ventures, Apax Partners, new businesses. It provides help in drawing up business Nomura, TVM, NIB Capital, Star Ventures plans and conducting market research and analysis. Advice 30 mil. euros: Igeneon AG, Vienna, August 2001 on patent law, assistance in identifying joint-venture part- 3i, Novartis Venture Fund, DVC, DB-Investor, ners and financiers, and a suitable infrastructure are also Dresdner Bank, CBG, Commerz Beteiligungsgesellschaft, made available. LISA is administrated by the Austria Capexit, Horizonte Wirtschaftsservice (aws, www.awsg.at) federal bank on behalf of the Federal Ministry of Economics and Labour. 27 mil. euros: Intercell AG, Vienna, July 2003 Apax, Nomura, TVM, GO Equity, In accordance with its corporate motto of "providing Sal. Oppenheim, Alpinvest financing from establishment to flotation”, pre-formation funding is available on favourable terms to allow for prepa- 27 mil. euros: Igeneon AG, Vienna, February 2004 ration of a technical proof of principle (pre-seed financing). Burrill & Co, 3i, DVC, Novartis Venture Fund, Mezzanine loans enable start-ups of young biotech compa- Capexit, gamma capital partners, Horizonte, Invest AG nies with an established technological foundation and high 11 mil. euros: Biovertis AG, Vienna, September 2004 growth potential (seed financing). Both forms of financing TVM, Kapital & Wert are intended to help bridge the interval between start-up and the availability of risk capital. 7.5 mil. euros: Fibrex Medical Inc., Vienna, March 2005 Venture-capital investments can then be backed by Global Life Science Ventures, Atlas Venture, Austrian guarantees: as companies mature, aws provides EMBL Ventures, Mulligan BioCapital AG loans at competitive rates and growth financing in the form 10 mil. euros: Biovertis AG, Vienna, December 2005 of guarantees for business investments. Investors in TVM, Life Sciences Partners Austrian biotech companies include Atlas Venture, Global Life Science Ventures (GLSV), EMBL Ventures, Mulligan 42 mil. euros: Nabriva Therapeutics Forschungs GmbH, BioCapital and TVM Life Science Ventures. February 2006 Nomura Phase4 Ventures, Wellcome Trust, HBM Partners, In addition, silent investments are very popular in Global Life Science Ventures, Novartis Venture Fund Austria’s biotech scene due to special tax reductions. ❚

116/2006 austriantrade.org 7 AUSTRIAEXPORT

Vienna © CPG/GF Life Scienes in Austria 5 universities ~ 100 primary companies with R&D strong focus in medical biotechnology, Tyrol drug development, diagnostics and 3 universities process development 36 primary companies with R&D strong focus in medical technology & informatics, drug development, bioanalytics & cell therapy

Styria 4 universities 19 primary companies with R&D strong focus in medical technology, R&D intensive primary companies pharmaceutical process engineering & health management

Biotech made in Austria

In the past decade Austria has proven itself to be an excellent location for research and development in the life sciences. A welcoming business environment, a prime location at the heart of Europe and its high quality of life all contribute to leveraging biotech growth in the country.

Beyana Maghakian

ustria is not only famous for musicians such as Today’s focus: medicine Wolfgang Amadeus Mozart, whose 250th birthday is Abeing celebrated in the year 2006; the field of medici- Modern Austria has successfully managed to maintain its ne has always possessed great significance here. When looking strong medical tradition, and pharmaceutical giants such as back at the country’s history, many important contributions to Sandoz Baxter, Boehringer Ingelheim and Novartis operate groundbreaking progress in the life sciences stand out. research and production facilities here, and as a result, bio- For centuries, the persistent innovative spirit of Austrian pharmaceuticals and bioprocessing are priority areas. scientists has led to numerous discoveries which represent Companies like Eli Lilly and Roche are important research milestones in medicine, biology, chemistry and other scien- contractor for the academic community in Austria. With the tific fields. In 1847, Ignaz Semmelweis for the first time aim of satisfying the daily needs of hospitals and medical introduced antiseptic measures for the prevention of child- practitioners, a number of small and medium-sized compa- bed fever. Toward the end of the 19th century, Theodor nies develop diagnostic tools, innovative services and novel Escherich discovered the most important bacterium used in treatments. biotechnology, Escherichia coli. And in 1901, Karl In contrast to the concentration in red biotechnology, the Landsteiner identified the blood groups, which earned him plant and environmental sector can be described as rather the Nobel Prize. small. In total, the country hosts about 150 small and

8 austriantrade.org 116/2006 AUSTRIAEXPORT

medium-sized enterprises in the ﬁeld of life sciences. Many of these companies were founded as spin-offs by researchers from one of Austria’s 15 universities which engage in relevant activities, and these companies continue to beneﬁt from their excellent academic connections.

Biotech products increase in importance

Despite being an infant industry just 30 years old, the global biotechnology sector can look back on an impressive record of success. In 2004, Ernst & Young counted over 4,400 biotechnology companies worldwide with combined revenues of 54.6 billion US dollars. That means an increase of 17% compared to 2003. Today, biotech products already account for some 20% of the total pharmaceuticals market, and the proportion is expected to double by 2010.

Local specialities for a global discipline

The majority of Austrian biotech activities are concentrated in the Vienna Region, Tyrol and Styria. Numerous success stories have already been written there, and these locations are still the places to look for vibrant activity. Recently, Upper Austria and Lower Austria have also turned their Applications of biotechnological knowledge attention to biotechnology. will in the near future dominate most areas of daily life. Austria’s number one: the Vienna Region © WWFF

After Berlin, Vienna is the second largest university city in antibiotics, acquired Morphochem in 2005 to strengthen its the German-speaking world. There are more than 120,000 product pipeline. Austrianova has been granted orphan students currently studying and researching at its nine uni- drug status by European Medicines Agency for its medica- versities, and all the life sciences are covered at five of them. tion designed to treat pancreatic cancer. Life Optics is today Nevertheless, the medical field clearly dominates, with the world’s leading manufacturer of high-technology head- cancer research, immunology and dermatology being the mounted vision systems for surgeons. And TissueGnostics most outstanding areas. Together with excellent non-univer- has developed an innovative system for analysing whole cell sity research institutes such as the Novartis Institutes for groups and tissue samples which will be used in routine dia- BioMedical Research (NIBR) and Boehringer Ingelheim’s gnostics. Research Institute of Molecular Pathology (IMP), Vienna’s Strong support is provided by federal and regional autho- universities provide a perfect environment for high-tech rities. For example, Life Science Austria Vienna Region companies. (www.lisavr.at) was founded as a central consultancy and There are a variety of excellent hospitals, and Vienna’s coordination centre for researchers and entrepreneurs. General Hospital is one of the largest in Europe. LISA VR channels the various kinds of support made avai- Multinational enterprises such as Baxter, Boehringer lable by its co-initiators, i.e. Austria Wirtschaftsservice Ingelheim, Novartis and top-ranking biotech and medtech (www.awsg.at) and Vienna’s Center for Innovation and companies as well are taking advantage of this environment. Technology (www.zit.co.at), and offers professional assistan- Since 1998, there have been approximately around 50 ce and financing for start-ups. biotech start-ups, the majority focusing on red biotechnology. Together with the big players, these research-oriented Working in a holiday region: biotech in the Tyrol enterprises employ about 6,500 people. The successful flotation of Vienna-based Intercell in Tyrol is known throughout the world as an excellent place spring 2005 marks the beginning of a new era for bioindus- for a holiday. But in addition to its beautiful landscape, it is tries in Austria. The first public-sector company in this field, also Austria’s second most important region for biotechno- it develops innovative "smart vaccines” and continues a logy, with some 3,000 people employed at 36 companies in strong Austrian tradition of immunological expertise. Other the life sciences. A total of 450 jobs have been created over start-ups have already managed to attract considerable the past three years, and another 2,300 researchers are wor- amounts of risk capital, the most recent examples are king at Tyrol’s universities, including the prestigious Nabriva focusing on novel antibiotics, Fibrex, which Leopold-Franzens University in Innsbruck, the Innsbruck specialises in the treatment of reperfusion damage, and Medical University and the newly founded private Biovertis. The latter company, which develops innovative University for Health Sciences, Medical Informatics and

116/2006 austriantrade.org 9 AUSTRIAEXPORT © HITT

In Austria, a noteworthy biotechnology scene which enjoys international recognition is already in existence.

Technology. The research performed in the fields of cell The Tyrolean Future Foundation (www.zukunftsstif- engineering, implant and implantation technology, medical tung.at) works to promote and develop the life sciences in device, health and bioinformatics, bioanalytics and drug the region. Part of this organisation is the Competence delivery enjoys international renown. Centre Medicine Tirol, where 111 researchers and entrepre- Tyrolean life-science companies benefit from academic neurs are currently collaborating on a total of 19 projects. know-how. For example, the AlcaSynn Pharmaceuticals From the very beginning, the Tyrolean Future Foundation company develops opioid receptor blockers for use in pain has also supported the Center for Academic Spin-offs Tyrol, therapy. Thiomatrix utilizes thiolated polymer systems for Health Information Technology Tirol and the Austrian mucosal delivery of biomolecules such as polypeptides, and Center Of Biopharmaceutical Technologies. Innovacell works on new cell-therapy processes to replace damaged muscle tissue. Healthcare technology in Styria: medical devices, white The health informatics company Icoserve designed an biotechnology and regenerative medicine advanced image-management software solution for hospitals. Over the past few years, about 50,000 square metres In Styria, the biotech scene is small but very dynamic. of lab and office space have been provided by public Two Graz-based companies, Oridis and ProtAffin, won Best authorities. of Biotech’s Central European business plan award for the life sciences two years in a row. Oridis, founded by Graz’s Medical University, concentrates on identifying molecular targets for the treatment of diseases. ProtAffin, a Karl- The level of education in the domestic Franzens University spin-off, develops genetically modified biotechnology sector is excellent compared to other countries. proteins for treating inflammatory illnesses. Transgenic animal models employed in the study of neurodegenerative diseases is the speciality of JSW Research, also based in Graz. Graz is also known as the home of the Kplus Research Center for Applied Biocatalysis. White biotechnology and upscaling technologies are rapidly growing in Styria. Companies such as VTU Engineering Ltd., Lactosan Ltd. and Zeta Holding are major players in the region. Total healthcare solutions, including testing facilities, are made available at the Center For Medical Research, where their partners perform clinical trials (phases 1-3). The life sciences in Styria also enjoy valuable support from © KMT Human.technology Styria (www.humantechnology.at). ❚

10 austriantrade.org 116/2006 AUSTRIAEXPORT Life Sciences in Austria © Croce&Wir © DAS KUNZFOTO

Human.technology Styria GmbH A-8020 Graz, Reininghausstrasse 13 T. +43/316/587016-0 • F. +43/316/587016-16 [email protected] • www.human.technology.at

Competence within the Cluster Networked for Success

The cluster human.technology.styria, founded in the summer ❚ Increase the number of companies with international presence of 2004, combines research and economy in the fields of medi- ❚ Increase the number of start-ups and spin-offs cine, biotechnology, process technology and engineering in ❚ Enhancement of competitiveness of existing companies the southern region of Austria. through enforced innovation The enormous potential of the network results from its unique density of competence. Our Vision: We are the preferred partner for international companies in Political Commitments the area of medical device and regenerative medicine. Through human. technology. styria is actively looking for cooperation the focus on "Integrated Health Care Solutions” we set a world- and synergies. Currently, we cooperate with Austrian institu- wide benchmark with our products and services. tions and companies as well as institutions in the South-Eastern markets and with selected international partners. To emphasize Fields of Excellence: the importance of this initiative, the cluster has been supported ❚ Key Competences in Therapies by the Federal Ministry of Economics and Labour and the Sty- ● Diabetes and Lipids rian Business Promotion Agency (SFG) right from the beginning. ● Intensive Care and Regenerative Medicine ● Hearing Impairment Ideal Infrastructure within a short Distance Based on the potential offered by five universities, numerous pri- ❚ Key Technologies vate-public research organisations, two polytechnics and appro- ● Process Engineering ximately 120 companies within a short distance, the cluster rein- ● Biocatalysis forces the cooperation between science and economy to create an ● Logistics area of competence in the field of human technology. All members of the cluster are identified by the "member of” – Logo. ❚ Key Research Areas ● Biometric Identification and Security Our Goals: ● Cell Biology and Tissue Engineering ❚ Establishment of Styria as an internationally competitive site ● Bioinformatics, Biosensors and Telemedicine for human technology ● Material Sciences and Nanotechnology ❚

116/2006 austriantrade.org 11 AUSTRIAEXPORT Life Sciences in Austria © BOKU © PID/Kullmann © WWFF

Life Science Austria (LISA) Vienna Region A-1010 Vienna, Ebendorferstraße 4 T. +43/1/4000-869 34 • F. +43/1/4000-7099 Sabine Ecker [email protected] • www.lisavr.at

Vienna Region as business location for Life Sciences Innovation meets Tradition

The Vienna Region has developed into an innovative centre ❚ Antibiotics: Biovertis, Nabriva, Pelias for the life sciences and it is a hub for Central and Eastern ❚ Allergology and immunology: Biomay, Onepharm, Sciotec Europe. Welcoming business environment, high quality of life ❚ Neuronal diseases: Affiris, Axon Neuroscience, Sanochemia and a prime location in the heart of Europe contribute to leveraging growth in the region. LISA VR — partner for scientists and companies Life Science Austria Vienna Region (LISA VR) is the central Global Players in the Vienna Region consulting and coordination office for life sciences in the A number of international companies are located in the Vienna Region and supports researchers and companies on Vienna Region and maintain R&D departments as well as pro- their way into a successful economic future. duction facilities. ❚ Assistance in starting a business and drawing up business plans ❚ Baxter: vaccines and blood plasma products ❚ Funding of start-up activities e.g. proof of principle (proto- ❚ Boehringer Ingelheim Austria: biopharmaceuticals and typing) in cooperation with university business incubators oncology; Research Institute of Molecular Pathology ❚ National and regional grants, subsidized loans and gua- ❚ Novartis including the Novartis Institute for BioMedical rantees Research Vienna ❚ Investor network ❚ Eli Lilly including its Vienna School of Clinical Research (VSCR) ❚ Training and networking: lectures, seminars, business plan competi- Sustainable Growth of the Life Science Community tions Since the late 1990ies about 70 start-ups were founded in ❚ Consultancy and net- Vienna. Together with universities, research institutes and the work contacts for re- big players on site they form a thriving Life Science commu- location projects ❚ nity. The main focus of these companies is medical biotechnology with the following priority areas: ❚ Vaccines: Intercell (IPO at the Vienna Stock Exchange in 2005) ❚ (Viral) cancer therapies: Austrianova; Greenhills Biotech- nology

12 austriantrade.org 116/2006 AUSTRIAEXPORT Life Sciences in Austria © Fotostudio Leutner

OÖ- Technologie- und Marketinggesellschaft m.b.H. A-4020 Linz, Hafenstraße 47–51 T. +43/732/79810-5005 • F. +43/732/79810-5008 Mag. Gerlinde Pöchhacker [email protected] • www.ooe2010.at

Life Sciences - a technology of the future in Upper Austria!

Extensive know-how and potential among companies and well as a diversity of small and medium-sized companies from research bodies the sub-supply sector. The predominant factor in this regard is Upper Austria is the leading federal province with regard to medical technology, which is to be the object of expansion. commerce, industry and exports. Moreover, the role of bio- ❚ Foods. Almost 200 companies are active in this economic sciences and biotechnology in Upper Austria is to be massive- segment. The competent further development of foods tech- ly enlarged. This expansion is foreseen in the “Innovative nology is an important factor in international competition. Upper Austria 2010” strategic programme. Keywords: functional food, proteins, lactose, enzymes, etc. ❚ Environmental technology. Around 100 enterprises are invol- Expansion in the education and research areas ved in this rapidly expanding, internationally oriented sector. Education and research are of fundamental importance. The Biotechnology is supplying impulses for production innovations establishment and growth of courses in Medical Technology, such as filter membranes in wastewater and waste treatment. Bio- and Environmental Technology and Bio-computing at ❚ Industry. Many of Austria’s leading industrial companies are Upper Austria’s Advanced Technical Colleges and the focus on based in Upper Austria. Interesting areas of application in the bio-systems analysis at the Johannes Kepler University of Linz Life Sciences field include process technology in the chemicals typify activities in these areas. Moreover, the Upper Austrian and pharmaceuticals sectors, as well as in the paper industry. Research (UAR) Centre for Biomedical Nanotechnology is already involved in the federal research programme. While in the Positive preconditions for commerce and industry. Companies schools’ area, the integration of biotechnology into the curricula planning to enter this sector find an excellent framework proof the Higher Technical Colleges for Chemical Plant Technology vided by the Health and Foods Clusters and the Environmental and Foods Technology has generated considerable effects. Technology Network. Companies are assisted in their activities and on the path to new technologies and inter- Close integration of business into the Life Sciences strategy national markets. In summary, it can be stated For Upper Austria, four areas of application are of major that the Life Sciences sector is booming, the significance. preconditions are positive and an entry into ❚ Health. Upper Austria already provides a the area will pay off. Upper Austria has a home to market leaders such as General great deal to offer and forming your own Electrics (GE) and Greiner Bio One, as opinion is more than worthwhile! ❚

116/2006 austriantrade.org 13 AUSTRIAEXPORT Life Sciences in Austria zVg ecoplus © Thule Jug © NÖW Helmut Lackinger ©

Technopol Krems Technopol Tulln Magnesitstraße 1 Technopark 1 A-3500 Krems A-3430 Tulln T. +43/2732/87470-230 T. +43/2272/61375-10 F. +43/2732/87470-70 F. +43/2272/61375-44 [email protected] www.ecoplus.at/technology [email protected]

Lower Austria – the home of high tech Innovative Strategies for Biotechnology

Technopols are combined technological and business centers Care), Tissuemed Bioscience, Baxter Bioscience, Cell Danube specifically established around recognized educational and and Cells+Tissue Bank Austrian are neighbors in the techno- research institutes. The Technopol Program of Lower Austria is pol´s Bio Science park. a trendsetter in implementing the linkage of education/training, research and business. Lower Austria’s three Technopols Technopol Tulln are already setting international standards: Technopol Krems in The Technopol Tulln focuses intensively on research and deve- the fields of biotech and regenerative medicine, Technopol lopment in the fields of agro- and environmental biotechno- Tulln in agro- and environmental biotechnology, Technopol logy. Biotechnical processes are developed in the areas of Wiener Neustadt in surface technologies, microsystems plant and animal production, as well as environmental pro- engeneering and medical engineering. tection. More than 200 highly specialized researchers are already active on-site. Technopol Krems The Research Institute for Agro-Biotechnology (IFA Tulln), a The city of Krems is pursuing an emphasis on biomedicine Department of the University of Natural Resources and Applied (tissue engineering, cellular therapies, extracorporeal blood Life Sciences in Vienna, ranks among the leading research insti- purification) and healthcare services. Krems’ biomedical pro- tutes in Europe in the fields of biotechnology in animal and duction processes and laboratory facilities meet the highest plant-production, bioanalytics, environmental biotechnology standards both for Austria and for the EU. and technology of natural materials. The University of Applied The Campus Krems with Danube University, IMC University of Sciences Wiener Neustadt in Tulln meets the demand for tech- Applied Sciences, and the Bio Science Park are the pillars of nical education in the field with its course of Technopol Krems that is setting new directions in biomedici- study in “Biotechnical Processes”. Specia- ne, pharmaceuticals and related health science sectors. And lisation in “natural materials technology” the best evidence that they are the right directions is the and “bioanalysis and monitoring” provi- host of international businesses striving des skilled scientists of global caliber. for Krems. In the new Technology Center Tulln in- Internationally recognized compa- ternationally operating companies and nies, like Ars Arthro Biotechnologie, start-up’s, like Romer Labs®, Biopure, Biotec Systems (Fresenius Medical 55Pharma and Biomin are located. ❚

14 austriantrade.org 116/2006 AUSTRIAEXPORT Life Sciences in Austria Kompetenzzentrum Medizin Tirol Kompetenzzentrum Medizin ©

Tiroler Zukunftsstiftung A-6020 Innsbruck, Kaiser-Jäger-Str. 4a Contact: Dr. Harald Gohm T. +43/512/57 6262 • F. +43/512/57 6262-10 [email protected] • www.zukunftsstiftung.at

Tirol as a Location for Innovation Working where others spend their holidays

When you think of Tirol in Austria, you usually think of holi- maintains the largest production plant for generic medicaments days. Tirol fulfils all the wishes one can hope for as a holiday- there. Tirol’s unique location between the most important maker in the Alpine region – 4,500 mountain peaks, hundreds European economic areas has strongly shaped its economic of mountain lodges, umpteen million square metres of powder development. The close proximity to the centres of population snow, 3,500km of ski slopes and uncountable culinary delights. concentration in southern Germany (Munich 160km), Nevertheless, when we speak of Tirol as a business location, Switzerland (Zurich 200km) and in northern Italy (Milan there is one thing we should not forget: apart from tourism, 370km) predestine Tirol’s industries as specialised suppliers for Tirol has developed into a specialised high-tech location. larger industries. Ideal transport connections make Tirol a hub for the international exchange of goods and knowledge. Tirol as a business location - mountainous habitat, healthy business Tirolean Fortitude The Tirolean economy has a small structure. Thousands of small Along with the exceptional position of its location, Tirol offers and medium-sized companies operate in the various areas of an economic area with further advantages for companies and the production, trade and service industries. The balanced employees. Three universities, two colleges of higher education representation of industry guarantees healthy economic and also technical schools ensure an excellent standard of edu- growth. Tirol leads the way in Austria with 1.9% growth last cation. Professional customer-orientated administration and year. The gross value added in Tirol was approximately 16.9 politicians who act as direct contacts for economic matters gua- million euros. Next to small and medium-sized companies, the rantee flexible and uncomplicated bureaucratic procedures. In larger domestic companies are also responsible for this. These combination with the high standard of living, these are larger companies impress worlwide with their know-how and noticable advantages for a location. The high level of quality. The Tyrolean Life Science Research fields combination of qualified jobs and optimal of cell engineering, implant- and implantation technology, leisure time possibilities, embedded in medical device, health- and bioinformatics, bioanalytics unique natural surroundings, attract top and drug delivery are internationally international executives to Tirol. established. The first industrially Are you interested in further information? manufactured Penicillin was made in Then please don`t hesitate contacting us: the small village of Kundl. Sandoz www.wirtschaftsstandort-tirol.at ❚

116/2006 austriantrade.org 15 AUSTRIAEXPORT Pharmaceuticals

Dr. Ernst Agneter, Associate Professor, MBA

Pharmaceuticals Research and Development

Agneter PharmaConsulting GmbH Mariahilfer Strasse 71 / 15 A-1060 Vienna Pharmacoeconomics T. +43/1/5264244 F. +43/1/5264366 Agneter PharmaConsulting GmbH Assoc.-Prof. Dr. Ernst Agneter , is specialized in pricing and reim- MBA bursement issues [email protected] www.pharmaconsulting.at

The founder of Agneter PharmaConsulting is As pricing and reimbursement questions are a trained physician and specialized in phar- gaining importance and complexity, Agneter macology and toxicology. With the experien- PharmaConsulting provides a full service in ce at the Federal Institute of Experimental working out strategies and preparing reim- Pharmacology (Ministry of Health), Dr. bursement dossiers. All necessary docu- Agneter has dealt with preclinical and clinical ments and negotiations for the Federation of expert reports for marketing authorization of Austrian Social Security Institutions” (FASSI) medicinal products. After several years in the are discussed with our clients and complete- Institute of Pharmacology at the University of ly done by us. Vienna and in the Department of Clinical Pharmacology at the General Hospital of As chairman of the health economics and Vienna Dr. Agneter was appointed Medical reimbursement committee of PHARMIG and Marketing Director of an international (Austrian Association of Pharmaceutical pharmaceutical company in Austria. Manufacturers), Dr. Agneter is working with several pharmaceutical companies. In 2001 Agneter PharmaConsulting was founded with the scopes of clinical expert reports, As board member of "Life Sciences Vienna" drug evaluation, pricing and reimbursement 2004 and chairman 2006, we are also focu- and strategic advice on clinical trails. sing on Biotech start-ups. ❚

16 austriantrade.org 116/2006 AUSTRIAEXPORT Pharmaceuticals

Biopharmaceuticals Plasmid DNA Contract Manufacturing Microbial Fermentation

Boehringer Ingelheim Austria 6,000 L, designed for high cell density pro- Committed to Quality, Technology cesses requiring high oxygen demand and high heat removal. Products are highly puri- Leadership and Business Process fied in modern recovery and purification Excellence Boehringer Ingelheim units. Columns up to 1.6 meters and techni- Austria GmbH ques such as adsorption, size exclusion, Dr. Boehringer-Gasse 5-11 hydrophobic interaction or ion exchange are Boehringer Ingelheim Austria is one of the A-1121 Vienna applied. Explosion-proof areas allow steps biggest pharmaceutical entities in Austria. It T. +43/1/80105/2141 requiring the use of organic solvents or large is a 100 % affiliate of the Boehringer Ingel- F. +43/1/80105/2440 scale high performance liquid chromatogra- heim group, one of the world’s 20 leading Dr. Monika Henninger phy. The plants are approved multi-product pharmaceutical companies. As the "Regional [email protected] facilities registered with the Austrian Health Centre Vienna”, the site is responsible for the ingelheim.com Authorities, the EMEA, and the FDA. www.boehringer-ingelheim.at Austrian market as well as for 28 countries in Central and Eastern Europe. Our Process Science Team guarantees a con- Besides pharmaceutical business and oncolo- stant supply of innovative technologies the- gy research, Boehringer Ingelheim Austria is reby improving process economy, robust- recognised as one of the world’s premier ness, product safety and quality. For our Contract Manufacturing Organisations. As a highly competitive and large scale plasmid "one-stop-shop” we offer the complete range DNA manufacturing technology which has of services from cell banking to large scale set the standard within the biopharma indus- GMP manufacture of drug substance and try, Boehringer Ingelheim Austria was gran- drug product. We focus on the development ted the Frost & Sullivan Technology Leader- and manufacture of microbial derived bio- ship Award in 2005. Also in 2005, we recei- pharmaceuticals, such as proteins, plasmid ved the Customer Value Award for provi- DNA, antibody fragments and protein scaf- ding our international clients with the hig- folds. In state-of-the-art GMP facilities we hest quality customer manufacturing. manufacture products for clinical trials and market supply. Value through Innovation. With our motiva- ted and highly qualified staff, we are dedica- Large scale GMP manufacture ted to keeping our premier position in con- As proven by our history, Boehringer Ingel- tract development and manufacture through heim Austria is committed to growth. Today, technology innovation, quality and regulato- the site operates 3 plants for microbial ry compliance, as well as business process fermentation with fermenter sizes up to excellence. ❚

116/2006 austriantrade.org 17 AUSTRIAEXPORT Pharmaceuticals

Mycoplasma Control of Biopharmaceuticals Mycoplasma Detection & Identiﬁcation Regulatory Testing (PhEur & FDA) Contract Research & Development

The Mycoplasma Specialist biologicals and biopharmaceuticals licensed Mycosafe is a leading expert by international agencies, such as the EMEA and the FDA, have been tested by Mycosafe. for mycoplasma control of Mycosafe Diagnostics Mycosafe’s mycoplasma testing services biopharmaceuticals GmbH include GMP-compliant testing methods Veterinaerplatz 1, Campus according to regulatory standards specified Mycosafe was originally founded in Decem- University of Veterinary Medicine by the European Pharmacopoeia (PhEur) and Vienna ber 2003 by Professor Renate Rosengarten the US FDA, as well as less stringent DNA A-1210 Vienna under the name Mycoplasma Testing & amplification methods (PCR). The PhEur- and T. +43/1/250 77-2150 Consulting GmbH as the first and only com- F. +43/1/250 77-2190 FDA-specified testing procedures apply to all pany in Austria and one of the few in Europe Professor Renate Rosengarten, biologicals and biopharmaceuticals produced offering a wide range of mycoplasma testing, DVM, PhD in cell substrates and include a DNA staining consultancy and research-related services for [email protected] procedure using indicator cell cultures to the GMP-compliant quality control of cell www.mycosafe.at detect “non-cultivable” mycoplasmas, in lines and cell culture-derived biologicals in addition to broth and agar culture procedu- research, biopharmaceutical processing and res. Mycosafe also offers PhEur and US FDA production. Located on the campus of the compliant validation studies to qualify each University of Veterinary Medicine Vienna mycoplasma testing assay for the respective and having its roots in the Institute of product to be tested. In addition, Mycosafe Bacteriology, Mycology and Hygiene, a uni- offers its expertise in mycoplasma species versity institute which is internationally identification and strain characterisation recognised for its research on mycoplasmas, using molecular techniques, and also provi- Mycosafe is well-positioned to become a des consultancy and training services in the mycoplasma testing service center and devel- area of mycoplasmology. oper of new mycoplasma testing assays of In cooperation with academic and industrial the future. partners, Mycosafe is developing and valida- Since December 2004, Mycosafe is operating ting new innovative DNA-based testing sys- under the new name Mycosafe Diagnostics tems for the detection and identification of GmbH and is today considered as a leading mycoplasmas. Following acceptance by the contract service and research organisation regulatory authorities, it is expected that which plays an important role in the success these easy-to-handle new molecular techno- of its clients in research and biopharmaceuti- logies, which provide results within a few cal production by assuring the mycoplasma hours, will be increasingly used as an alter- biosafety of cell banks, in-process samples, Mycoplasma-contaminated cell line native or additional method to the current lot-release samples and raw materials. Several time-consuming standard procedures. ❚

18 austriantrade.org 116/2006 AUSTRIAEXPORT Pharmaceuticals

Dr. Atkins: Cancer can be reversed

Pharmaceuticals Anticancer drug

149 scientists from 16 countries in 47 universities and research institutes have carried ® UKRAIN® out detailed tests on UKRAIN and publis- “ hed their results in more than 120 scientific The powerful anticancer drug papers indicating the importance of Nowicky Pharma UKRAIN® for cancer therapy. Dr. Atkins Margaretenstraße 7 regards UKRAIN® as the single best antican- A-1040 Vienna ® UKRAIN is a derivative of alkaloids from T. +43/1/586 12 23 cer agent he has used to date. "Like chemo- the plant greater celandine and the pharma- F. +43/1/586 89 94 theraphy, it kills cancer cells very well, but, ceutical thiotepa and is used in the cancer Dipl. Ing. Dr. Wassil Nowicky unlike chemotheraphy, it spares normal therapy. Both of these substances are appro- [email protected] cells, healthy tissue. If the medical commu- ved as human drugs and are commonly used www.ukrin.com nity were willing to give it a try, UKRAIN® in hospitals. could replace chemotheraphy in treating In contrast to cytostatica, the inhibition of almost all cancers." - Robert C. ATKINS, M.D. cell division by UKRAIN® is confined to tumour cells, while the cells of healthy tissue The Ukrainian Anti-Cancer Institute (UACI) is remain unaffected. Excellent tolerance to a non-profit organization dedicated to free UKRAIN® therapy is a result of this fact. The and independent scientific research on drug is easy to use and the therapeutic dose UKRAIN®. To the present day 16 countries has no significant side effects. have participated in the UACI research with more than 150 scientists in 46 universities The main advantage of UKRAIN® is that it and research institutes. The results of UACI selectively kills cancer cells and fortifies the research are regularly presented on interna- body's defences. UKRAIN® destroys cancer tional congresses and published in scientific cells through apoptosis without attacking magazines. healthy cells,thereof results the excellent tolerance. Beside that, UKRAIN® does not The exciting story about the development of cause any kind of damaging side effects. UKRAIN® is examined by the science journa- list Eleonore Thun-Hohenstein. Reading UKRAIN® activates a whole series of highly about that, one wonders if this discovery is effective immune system mechanisms and suppressed because it is against some phar- brings about the encapsulation of tumours maceutical companies' interests. through antiangiogenesis (the inhibition of ” new blood vessels formation at the tumour Direct order: [email protected] site), thereby increasing operability. (Interview with Dipl. Ing. Dr. Wassil Nowicky) ❚

116/2006 austriantrade.org 19 AUSTRIAEXPORT Pharmaceuticals

Pharmaceuticals Research and Development Diagnostics Specialty Pharma Company

SANOCHEMIA Pharmazeutika SANOCHEMIA Pharmazeutika AG Boltzmanngasse 11 The Specialty Pharma Company A-1091 Vienna T. +43/1/3191456-0 F. +43/1/3191456-344 Sanochemia has elected to concentrate on Margarita Hoch An additional sphere of activity involves the the development and manufacture of inno- [email protected] manufacture and sale of radiological pro- www.sanochemia.at vative specialty pharmaceuticals in indica- ducts distributed through our Sanochemia tions with a high degree of therapeutic com- Diagnostics subsidiaries. Sales offices have plexity such as neurodegeneration, pain and been established in Germany, Switzerland, cancer. Our products target segments cha- the UK and USA. racterised by both unmet medical need and interesting revenue potential. Strategy – Our focus lies on those sections of the pharmaceutical value-added chain in Profile – Our strength and expertise lies in the which we have in the past amassed signifi- efficient management of complex pharmaceu- cant levels of expertise and experience. This tical development projects from pre-clinic encompasses developmental skills, regulato- through to registration. We consciously avoid ry procedures and the synthesis of complex broad-based and cost-intensive exploratory APIs and forms the key to a range of long- research. Extensive in-house skills and resour- term competitive advantages. The majority ces are supplemented by numerous top-level of our revenues are already generated scientific co-operations with contract research through product sales. organisations, institutes and universities. Profitable contract manufacturing orders, Sanochemia’s patented development of ste- API synthesis and imaging diagnostic sales reoselective synthesis processes for active all contribute to steady revenue flows. pharmaceutical ingredients (API) forms a Additional potential lies in pipeline develop- central factor underpinning our growth. This ments of new drugs for attractive segments in turn allows us to offer partners a wide of the pharmaceutical market. Our in-house range of services in the fields of contract syn- development projects are financed through thesis and manufacturing. operational cash flows. ❚

20 austriantrade.org 116/2006 AUSTRIAEXPORT Diagnostics

Research and Development reference materials Suppliers Anayltical Lab service

Making the world’s food safer

More then two decades of experience with mycotoxins and the close cooperation with Romer Labs Diagnostic Biopure Referenzsubstanzen GmbH GmbH, recognized international universities provi- www.biopure.at TZT, Technopark 1 des us access to information about occurren- A-3430 Tulln ce, toxicological and health effects, influence T. +43/2272/615 3310-10 The basis of good analytical methods is the of food and feed processing and state of the M. +43 664 814 37 86 availability of appropriate reference material art technologies for testing. We use our expe- F. +43 2272-61533-111 of defined purity and concentration. How- rience and knowledge to help clients to set COO Gustav Kichler ever, the purity of mycotoxin standards is up a mycotoxin control system and to mana- [email protected] often uncertain. Founded in the year 2001, ge the risk. Biopure has developed world-leadership in the production of highly purified mycotoxin Biopure calibrants. Today thousands of labs in all con- Referenzsubstanzen GmbH Romer Labs Diagnostic GmbH tinents benefit from the liquid and solid cali- Technopark 1 www.romerlabs.com brants supplied from Biopure. A-3430 Tulln T. +43/2272/615 33 20 Romer Labs offers innovative and highly F. +43/2272/615 33 211 efficient solutions for Mycotoxin Testing Dr. Martin Freudenschuss Quantas Analytics GmbH Labs. [email protected] ❚ ELISA-test kits for Total Aflatoxin, www.biopure.at As a result of the cooperation with the IFA Deoxynivalenol, Zearalenon, Ochratoxin, Tulln – (Institute for Agrobiotechnology Fumonisin, T-2 Tulln) Quantas Analytics were founded ❚ Rapid test kits for Aflatoxin, DON – GIPSA Quantas Analytics GmbH recently in order to transfer research results approved Technopark 1 into a service for routine analysis. Because of A-3430 Tulln ❚ Clean up columns, Immunoaffinity new regulations, the testing of mycotoxins T. +43/2272/615 33 30 columns for chromatographic methods has become very important also for remote ❚ F. +43/2272/615 33 311 Sampling devices Dr. Hannes Binder places, where no Labs can be established. As part of the Technology Center Tulln, a focus [email protected] Therefore samples need to be sent to a is set in R&D, to ensure continuously new pro- www.biopure.at center of competence which takes care of duct output, which meets market demands. analyzing. ❚

116/2006 austriantrade.org 21 AUSTRIAEXPORT Diagnostics

Research and Development Suppliers Infertility treatment Testis, ovar & cervix cancer diagnostic

Vitateq Biotechnology LLC tory. Presently, there are no comparable products available on the market.

A company dedicated to human Very recently, Vitateq has discovered that afamin is also related to other diseases. Afamin fertility vitateq biotechnology exerts neuroprotective properties in neuronal GmbH cell culture models. These results indicate a Innrain 66 Vitateq focuses on the identification and in- A-6020 Innsbruck high potential for diagnostic and therapeutic depth characterization of proteins related to T. +43/512/504 25590 applications of afamin not only in the fields human fertility. Vitateq was the first to dis- F. +43/512/504 25599 of fertility and cancer, but also neuropro- cover that afamin, a human serum transport CEO Prof. Hans Dieplinger, PhD tection. protein for vitamin E, is a major player in the [email protected] development of reproductive tract tumors, www.vitateq.com Vitateq Biotechnology is a spin-off company infertility and neurodegenerative diseases. from the Medical University of Innsbruck with international management. The com- Vitateq has established an ELISA kit for pany’s knowledge-based technologies inclu- quantifying afamin in human serum as a de proteomics and state-of-the-art molecular novel diagnostic tool for early, improved and biology techniques. Our product develop- more specific detection of cancers occurring ment is protected by several international in human reproductive tissues. This ELISA patents. Scientists at Vitateq have more than kit is fully developed and has already been 15 years of extensive research experience on tested successfully in several human patient afamin, as documented by several publica- groups. Vitateq’s cancer diagnostic ELISA is tions in highly renowned international bio- ready for entering a large-scale clinical trial. medical journals, such as:

Furthermore, Vitateq is developing the world’s Characterization of the vitamin E-binding first IVF laboratory diagnostics for identify- properties of human plasma afamin (2002) ing human embryos with a high potential for Voegele AF, Jerkovic L, Wellenzohn B, Eller successful implantation in the uterus and P, Kronenberg F, Liedl KR, Dieplinger H. development into a full-term baby. Our new Biochemistry 41:14532-14538. diagnostic test will be based on a variety of Afamin is a novel human vitamin E-binding signiﬁcant and biologically relevant biomar- glycoprotein: characterization and in vitro kers. Such a product has an extraordinary expression (2005) Jerkovic L, Voegele AF, market potential because it is non-invasive, Chwatal S, Kronenberg F, Radcliffe CM et al. reliable and easy to use in a routine labora- J Proteome Res 4:889-899. ❚

22 austriantrade.org 116/2006 AUSTRIAEXPORT Research and Development

Research and Development Diagnostics

Make it visible males and females per year - and the low sig- Tumour Diagnostics in Motion - nificance of existing diagnostic approaches there is a high market potential for simple, To Be in the Know Increases Amynon Biotech GmbH fast and safe diagnostic test procedures. Quality of Life Innrain 66/III Amynon’s PapTec® assays are based on anti- A-6020 Innsbruck bodies that allow the highly specific detec- T. +43/512/504 25767 tion of the hr HPV-E7 oncoprotein in clinical Amynon Biotech GmbH, founded 2002 in F. +43/512/504 258 52 samples (smears, liquid based cytology, Innsbruck, Austria, is a biotechnology com- CEO Dr. Barbara Fitzky tumour biopsies, body liquids and cell ly- pany specialized in research and develop- [email protected] sates). In contrast to existing approaches, the www.amynon.com ment. Core competence of the company is to PapTec® does not detect HPV infections but study changes of gene expression and gives a positive signal in the case of a tumour function in human tissues during cancer development caused by hr HPV. development and ageing, with the intention Amynon’s second product line consists of to identify and validate new targets for early some assays for early diagnosis of age associ- diagnosis of tumour-, age- and environment- ated dysfunctions in the skin and cardio vas- induced diseases. Amynon develops diagnos- cular system. tic assays up to the prototype including ‘proof of concept’ studies. Partnerships Amynon Biotech GmbH follows an efficient Amynon’s first line of products, the PapTec® strategy to protect intellectual property and assays, are developed for the early diagnosis has filed several patents. The rights for proof HPV-induced tumour diseases, especially duction and distribution are licensed to part- cervical cancer and other anogenital cancers. ners from the pharmaceutical industry. As a The products are currently in preclinical trials. science-based and market oriented company At present, cervical cancer screening is the Amynon is permanently interested in inter- largest existing screening market in oncolo- national cooperations with diagnostic and gy. Worldwide, there are 470.000 new cases pharmaceutical companies to further deve- of cervical cancer each year causing more lop and commercialize Amynon's products. than 230,000 deaths. Human papilloma virus (HPV) induced cervical cancer is the Due to its innovative approach, which is most common cancer beneath breast cancer based on the latest scientific results, the pro- in women and, if detected early, cervical can- Make it visible - HPV-E7 oncoprotein ximity of the products to market demand cer is a fully preventable disease! Due to high detection in cervical smear. and a strong patent position, Amynon might HPV infection rate - more than 300 million be an interesting partner. ❚

116/2006 austriantrade.org 23 AUSTRIAEXPORT Research and Development

Drug discovery Preclinical Models Research and Development Clinical Studies

Apeiron Biologics enzyme for the therapy of this life-threate- Translation of biological discoveries ning lung failure. ACE2 is expected to be active against ARDS irrespective of the into novel biopharmaceutical underlying disease. products Apeiron Biologics A second project of Apeiron relates to the Forschungs- und biologic role of Cbl-b, a key check-point Apeiron Biologics GmbH is a biotechnology Entwicklungs GmbH molecule of the immune system. The enzyme company located in Vienna, Austria. Its objec- Brunner Strasse 59 Cbl-b has been recognized as critical negative tive is to develop novel and innovative drugs A-1230 Vienna regulator of autoimmunity. Modulation of T. +43/1/865 65 77 for the treatment of diseases with a high Cbl-b activity may enable effective vaccina- F. +43/1/865 65 77-9280 degree of unmet medical needs. The company Dr. Hans Loibner, CEO tion strategies against weakly immunogenic was founded by Josef Penninger, Director of [email protected] antigens such as cancer, malaria, HIV-infec- the Institute of Molecular Biotechnology of www.apeiron-biologics.com tion, or alternatively may lead to novel thera- the Austrian Academy of Sciences (IMBA), a pies for autoimmune diseases. In a strategic top-level scientist with high international partnership Apeiron identifies and profiles reputation. CEO is Hans Loibner, who has substances that interfere with Cbl-b activity. more than 25 years experience in Pharma In a third project, Apeiron in a strategic alli- R&D and has founded and successfully deve- ance identifies compounds that modulate the loped an Austrian biotech company. biologic action of DREAM, a key molecule Apeiron´s key project is the development of for the natural pain regulation by controlling a therapy for the Acute Respiratory Distress the expression of an endogenous opioid. Syndrome (ARDS). ARDS affects at least one Such compounds are expected to be power- million individuals worldwide/year and has ful analgesics, based on the induction of the a mortality rate up to 50%. Presently no drug production of an endogenous opioid. is available to treat this life-threatening con- Initial funding of Apeiron Biologics was pro- dition that is caused by a variety of diseases vided by its founders as well as by support such as sepsis and pneumonias due to viral institutions including "Austria Wirtschafts- infections (e.g. influenza, avian flu, SARS). service”(AWS), "Zentrum für Innovation und ARDS may be the key complication in the Technologie” (ZIT) of Vienna, and the Sixth context of the feared pandemic outbreak of a Research Framework Programme of the new influenza virus. There is now proof that European Union. Angiotensin Converting Enzyme 2 (ACE2) is Apeiron’s premises are located on the campus a central molecule for the development and of the Novartis Research Institute Vienna, progression of ARDS. In consequence, taking advantage of the impressive infrastruc- Apeiron develops a recombinant form of this ture of a big pharmaceutical company. ❚

24 austriantrade.org 116/2006 AUSTRIAEXPORT Research and Development

Quality Assurance / Q Management Services R&D Consulting Audits Marketing Authorisation Support

Total Quality Consulting CIS Clinical Investigation Support Pharmaforschung Clinical research & development, Gesellschaft m.b.H. Kaiserstraße 43 quality assurance and regulatory A-1070 Vienna affairs T. +43/1/523 40 15 F. +43/1/523 40 15-99 Dr.med. Dr.phil. Gerhard NAHLER [email protected] www.cis-qa.com Quality is the key factor for success. CIS S.A. has performed audits in more than Poor quality in R&D, from planning to the 30 different European and non-European conduct and analysis/reporting, is the main CIS Société Anonyme, countries such as e.g. Argentina, Austria, cause why studies fail or need to be repea- Place Rouppe 19, Australia, Belgium, Brazil, Canada, Denmark, ted, causing increased costs, delays, and the B-1000 Brussels, France, Germany, India, Israel, Morocco, The risk of having the marketing authorisation of Netherlands, New Zeeland, Portugal, South a product denied. Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States, including CIS considers quality assurance services not also a large number of countries in Eastern only as an instrument to increase or main- Europe, such as Belarus, Bulgaria, Czech tain quality as well as competition, but also Republic, Croatia, Estonia, Hungary, Latvia, to reduce costs. Lithuania, Poland, Romania, Russia, Slovakia, Slovenia, and Ukraine. CIS prepares compa- CIS has provided consulting & quality assu- nies for inspections by health authorities. rance services to more than 20 pharmaceutical companies including CROs. Most of them CIS offers consulting and project manage- have trusted CIS repeatedly with various ment services, starting from the switch pre- kind of projects, from early development to clinical-to clinical development up to sub- submission for Marketing Authorisation. mission for marketing authorisation. This includes also "coaching" of projects or staff- CIS has a broad experience in conducting training "on the job" in case of temporary audits in all major areas of clinical research. shortages of resources of the client. ❚

116/2006 austriantrade.org 25 AUSTRIAEXPORT Research and Development

Industrial Enzymes Human Antibodies Biopharmaceuticals Fermentation Optimisation

Facts about EUCODIS EUCODIS is an independent private compa- Innovations Made by Nature ny and financed by governmental research funding, venture capital and an increasing stream of income by research collaborations. EUCODIS GmbH EUCODIS GmbH founded in 2004 at Vienna, Beside its headquarter and main laboratories Brunner Straße 59 Austria, is a biotechnology company success- A-1235 Vienna at Vienna, EUCODIS has a subsidiary at one fully generating novel products in the life T. +43/1/866 34 9240 of the leading European research institutes, science area by applying the two most F. +43/1/866 34 449 Necker Faculty of Medicine in Paris. EUCO- powerful technologies mimicking natural CEO Wolfgang Schönfeld DIS staff size is about 25 co-workers. EUCO- processes of evolution, in vivo recombina- [email protected] und offi- DIS has a strong international network of tion and somatic hypermutation. [email protected] leading experts for its individual projects www.eucodis.com which ensure optimal project design and Technology Base of In Vivo Recombination performance of research and collaborative Recombination of genes is normally limited projects. In industrial enzymes EUCODIS is to very high DNA sequence homology. The member of the Competence Center for EUCODIS proprietary approach extends Applied Biocatalysis at Graz, Austria. Major these natural limitations to recombination of research collaborations with the Necker highly diverged sequences and thus creates Faculty of Medicine and leading institutes in proteins with novel properties coded by the Europe linked via a major grant from EU recombined gene sequence. EUCODIS has focussing on human antibodies are in place. set up proprietary tools which efficiently and quickly create highly diversified libraries. Within shortest time EUCODIS could EUCODIS demonstrated the superiority of its demonstrate the validity and power of its technology in several projects: generation of technologies and know-how by a number of libraries with a high percentage of active pro- industrial collaborations such as Sanofi- teins and broadest diversity – more needles Aventis, Biocatalytics Inc, and PLIVA, in a smaller haystack! Croatia. In addition to these collaborative service agreements, internal projects are Technology Base of Somatic Hypermutation focussed on biopharmaceuticals (anti-inflam- The EUCODIS approach mimics the affinity mation and bone metabolism) and two maturation process by which mammalian important enzyme classes. EUCODIS expects organisms generate high affinity antibodies. to enter preclinical development in 2007 by Iterative stimulation of a human B-cell line its internal projects whereas first industrial allows the generation of specific, human enzyme products for licencing are available antibodies or novel biopharmaceuticals. in 2006. ❚

26 austriantrade.org 116/2006 AUSTRIAEXPORT Research and Development

Pharmaceuticals Anti-inﬂammatory peptides Research and Development Myocardial infarction

Fibrex Medical damage of the heart muscle after experimen- FIBREX Medical is developing new tal myocardial infarction. Recently, FIBREX Medical has filed an IMPD drugs for serious inflammatory for the treatment of cardiac reperfusion inju- desease ry and has completed phase I clinical trials in Q4/2005. In parallel, research programs for Fibrex Medical Research & additional indications for FX06 will be con- FIBREX Medical Inc. is a development stage Development GmbH ducted and suitable indications for clinical bio-pharmaceutical company. Its operational Brunnerstraße 59 development will be identified, with an affiliate Fibrex Medical Research & Deve- A-1235 Vienna emphasis on septic shock. New peptides T. +43/1/86634-9270 lopment GmbH was established in Vienna in already identified will be analysed with res- F. +43/1/86634-9279 February 2001. Concurrently with the foun- Dr. Rainer Henning pect to their usefulness for autoimmune dation of the U.S. holding company, FIBREX rainer.henning@fibrexmedical.com diseases. In Q2/2006, FIBREX Medical will Medical has completed a US $10 million www.fibrexmedical.com begin a phase IIa clinical trial of FX06 in car- Series financing round in March 2005 co-led diac reperfusion injury to achieve the proof by Atlas Venture and Global Life Science of concept in man. In parallel, partnering Ventures (GLSV). The company aims to beco- discussions with a pharmaceutical partner me a leader in the development and com- for performance of phase III trials and commercialisation of pharmaceuticals targeting mercialization will be started. Phase IIa trials fundamental mechanisms of inflammation- for additional indications for FX06 will be based tissue injury. Using its automated initiated in 2007. screening technology, FIBREX Medical has FIBREX Medical currently concentrates its identified several anti-inflammatory pepti- efforts on the preclinical and clinical deve- des. Inflammation-based tissue injury is well lopment of the products currently in its pipe- known as a major component in the patho- line. However, in-licensing of product candi- genesis of important diseases, such as myo- dates (late preclinical or early clinical) with a cardial infarction, septic and hemorrhagic strategic fit will actively be pursued to com- shock, graft rejection or rheumatoid arthri- plement the pipeline. Research activities for tis. The most advanced development product profiling its product candidates will be done of FIBREX Medical – a peptide with the code in close collaboration with the laboratories FX06 – is developed for the indication cardi- of the company´s scientific founders as well ac ischemia/reperfusion injury; it aims at as its scientific network. markets with more than 5,000,000 potential FX06 reduces infarct It is expected that FX06 will be out-licensed patients per year in the developed world. In in experimental models. to a pharmaceutical company in the course animal studies FX06 significantly reduced of clinical phase II. ❚

116/2006 austriantrade.org 27 AUSTRIAEXPORT Research and Development

Online Analytics Trace Gas Analysis Process Monitoring VOC Quantiﬁcation

Ionimed Analytik avoids fragmentation, exact mathematical Online trace gas analysis for use in models may be used to accurately quantify the detected masses of compounds. Another the biotechnology and medical benefit of our products using H3O+ ions is that the results of PTR-MS measurements are industries Ionimed Analytik not modified or falsified by high concentra- G.m.b.H. tions of water vapor in the gas samples to be Technikerstr. 21a Ionimed Analytik GmbH is a young spinoff A-6020 Innsbruck analyzed. company in Innsbruck, Austria with exper- T. +43/512/507-4810 tise in the detection and quantification of trace F. +43/512/507-9818 Compared to ordinary gas chromotography, gases in air using proton-transfer-reaction Dr. Armin Hansel our PTR-MS system provides the possibility mass spectrometry (PTR-MS), specifically for [email protected] of online and real-time measurement, be- the fields of biotechnology and medical re- www.ionimed.at cause the instrument's response time is less search. High quality PTR-MS instruments for than 100 ms. There is no need for any satisfied customers from industry, university sample preparation before injection into the and private research have been employed in PTR-MS inlet. the food and fermentation control industries as well as for process and environmental For example, PTR-MS can be applied to the monitoring. The very low detection limit for following: volatile organic compounds (VOCs), real- ❚ Process control in biotechnology by head time measurements due to fast response space monitoring of VOCs emanating from times, and continuous monitoring capabili- fermentation ties are the major advantages of our innova- ❚ Evaluate cell processes by characterization tive PTR-MS system. of emitted VOCs ❚ Non-invasive diagnosis for the medical PTR-MS technology was developed by scien- industry via sensitive detection of VOCs tists at the Institute of Ion Physics at the from exhaled breath that can be used as Leopold-Franzens University in Innsbruck. A markers (e. g. for the prerecognition of soft (low fragmentation) ionization method disease) based on proton transfer reactions from H3O+ ions to all compounds with a higher In addition to offering a variety of instru- proton affinity than water is used in our ments incorporating PTR-MS technology for device. This leads to our unique low detec- sale, Ionimed Analytik offers instruments for tion threshold for trace compounds in the Compact real-time VOC detector. hire as well as expert analysis by our team of range of a few pptv. Since our technique gas samples containing VOCs. ❚

28 austriantrade.org 116/2006 AUSTRIAEXPORT Research and Development

Pharmaceuticals Alzheimer Parkinson Drug Development Contract Research Clinical Preclinical Pain Inﬂammation

JSW-Research ding transgenic disease models. Dr. Aging with a Clear Mind Windisch, CEO of JSW-Research: For the identification and evaluation of compounds we apply a broad spectrum of biochemical, cell biological and molecular biological Research focused on finding powerful treat- JSW - Research methods. Furthermore we are specialists in ment strategies for age related brain diseases Forschungslabor GmbH neuroscience and behavior and work with is the central purpose and responsibility of Rankengasse 28a various animal models including transgenic JSW-Research. A-8020 Graz mice. Dr. Windisch founded the company in T. +43/316/765114 22 1999 and gained profound knowledge F. +43/316/765114 4 The company is also dedicated to providing during a 20 year career in drug research. In Robert Wronski, PhD, MBA top-level clinical research on a broader range [email protected] the preclinical field JSW-Research focuses on of illnesses throughout all stages of therapy www.jswresearch.com age related diseases of the central nervous development. system: Alzheimer’s disease, Parkinson’s disease, vascular dementia but also cerebro- JSW-Research Ltd., Graz, Austria, offers vascular disease mediated neurodegenera- comprehensive research and consulting pro- tion. The clinical department of JSW- grams for drug development concerning Research offers services in all clinical phases disorders of the central nervous system. and indications. JSW-Research uses modern molecular biology techniques and has also designed a varie- JSW-Research generates high quality research ty of disease relevant cell and animal models on two levels: First the company performs for characterizing drug effects. Interlacing highly standardised contract research for the modular systems facilitate step-by-step analy- pharmaceutical industry and for well renown sis of candidate substances from basic in institutions like Harvard University, Mayo vitro to complex in vivo assays, complemen- Clincs and the University of Tel Aviv. 99% of ted by a full range of histological, biochemi- JSW’s customers come from abroad. cal and behavioral evaluation methods. Academia represents a significant proportion of the customers, since the Austrian enterpri- The Austrian contract research and drug se is one of the technology leaders regarding development company JSW-Research has preclinical and clinical research. In a second specialised on the performance of experi- branch JSW-Research performs proprietary mental and clinical studies in the field of drug development programs. It is the primary neurodegenerative diseases. The enterprise goal of the company to improve the quality of has internationally accepted expertise regar- life of patients and their relatives. ❚

116/2006 austriantrade.org 29 AUSTRIAEXPORT Research and Development

Management of industrial research Nano-(Bio)Technology and Bioanalytics Consulting and services Phyto-Pharmaceutical, Cell Therapy and Implant Technology

Center for Life Sciences years, plant based medicines will become an KMT is expanding its services in the additional research focus. KMT manages large research and co-operative programmes on a area of Life Sciences research Kompetenzzentrum national and international level. The Kompetenzzentrum Medizin Tirol Medizin GmbH (KMT) located in Innsbruck, Austria, was Leopoldstraße 1/3 OUR SERVICES founded in 2002 and is an industrial center A-6020 Innsbruck International and national research of excellence for companies and research T. +43/512/576526 project management F. +43/512/576526-4320 institutions in the life sciences sector. Inno- ❚ Screening of national and EU calls GF Gordon Koell ❚ vative research projects with high develop- [email protected] Project design, implementation and ment and marketing chances are ﬁnanced www.kmt.at management and managed by the Kompetenzzentrum ❚ Development of project proposals Medizin Tirol (KMT). The main areas of research are implant technology, bioanalytics, Networking with industrial and academic cell therapy and nano-(bio)technology. partners With regard to project management, KMT ❚ Assistance in partner searches has specialist experience and expertise in ❚ Reporting on international trends and project planning, together with developing trade shows and managing project proposals, particularly in the area of life sciences. Consulting & Services As part of the contribution to the European ❚ Finance and budgeting research agenda, KMT is extending its custo- ❚ Marketing and communications mer services and promoting development of ❚ Project management the Life Science Cluster Tirol at an interna- ❚ Organisation of workshops, meetings and tional level. KMT, as a center of excellence, conferences has well established contacts with key stake- holders (industry, academic, public autho- Center of excellence rities) in life sciences in the region and ❚ FP6 and upcoming FP7 – Life Sciences beyond. ❚ Genomics and Biotechnology for Health The ﬁrst results from research and develop- ❚ GEN-AU Projects ment activities of some KMT projects have ❚ Interdisciplinary FTE projects, Austrian already been successfully introduced onto the Nano Initiative – Nano Diamond Network market. The Tyrol region in Austria is particu- Implant technology; bioanalytics; ❚ fFORTE-FEMtech larly strong in the areas of cell therapy, immu- cell therapy; nano-(bio)technology. ❚ K_ind / K_net Programmes nology and bioanalytics. During the next few ❚ REGplus ❚

30 austriantrade.org 116/2006 AUSTRIAEXPORT Research and Development

Research and Development Diagnostics Development and Production of DNA Chips DNA Analysis

Lambda GmbH for quality assurance within the pharmaceu- Laboratory for Molecular-biological tical industry. The combined expertise of Lambda and Greiner Bio-One comprises the DNA Analysis development and production of a new innovative high-throughput biochip platform (High-Throughput microArraying, HTA™ The use and development of modern micro- Lambda GmbH Slide) for the parallel analysis of samples, the technologies are opening up new opportuni- Industriestraße 6 selection of appropriate sequences and pro- A-4240 Freistadt ties for medicine and research in the ﬁeld of bes and the validation and production of in T. +43/7942/75055-900 diagnostics. Since its foundation in the year vitro diagnostics according to the European F. +43/7942/75055-910 1999, Lambda GmbH has responded to the Mag. Florian Winner Guideline 98/79/EG and the international challenges in this ﬁeld and now specializes in [email protected] quality management standard EN ISO a wide range of molecular biological me- www.lambda.at 13485:2003 for medical devices, respective- thods of detection. The innovative biotech- ly. Products consist of complete test systems nology company with its roots in Freistadt, with all the necessary buffers and solutions. Austria, develops and produces biochips as The on-chip quality-control system, for ready to use kits for applications in research which Lambda has already applied for a and routine diagnostics. DNA analysis and patent, guarantees perfect monitoring of customer research work are carried out by every stage of analysis and production and experienced specialists in Lambda's own therefore virtually excludes false negative laboratories. Through its close collaboration and false positive results. An IVD-compatible with associates in industry and research, microarray scanner together with an integra- Lambda assures the practicality and reliabili- ted analysis software permit the fully auto- ty of its solutions. Thus, the company which matic high-throughput detection and analy- is owned by the Greiner Bio-One GmbH, sis of up to four biochips at once. The develops biochips for the medical dia- Lambda-products are distributed worldwide gnostics. by Greiner Bio-One.

Development and Production of Biochips DNA Analysis Through their use in the screening of genetic For its customers, Lambda carries out a wide defects or infectious agents, biochips or range of DNA analyses based on state-of-the- "microarrays” represent one of the key tech- art technology. These include fatherhood tes- nologies of the future. Lambda develops and MycoDtect™ - test kit for the ting, detection of micro-organisms and ori- manufactures high-quality biochips for detection of Mycoplasma. gin tests of meat products using external and human diagnostics, consumer protection and in-house diagnostic products. ❚

116/2006 austriantrade.org 31 AUSTRIAEXPORT Research and Development

Research and Development Training and Education

A Centre of Excellence medical curricula in the world. The VSCR has Vienna School of Clinical Research pioneered a systematic postgraduate academic education. (VSCR) The VSCR courses can be taken as individual short courses to fill specific knowledge gaps. The Vienna School of Clinical Research plays Several courses together form curricula that an exceptional role as a new centre for break- are designed to meet the needs of investiga- through learning opportunities in the field of tors, ethics committee members, clinical clinical research. The VSCR has become a Vienna School of Clinical research associates etc. These pre-defined cur- "Centre of Excellence" for clinical research Research ricula are awarded diploma and widely recog- education. Since its foundation in 2001, P.O. Box 109 Kölblgasse 10 nized by academic centres. The current curri- A-1031 Vienna more than 1300 doctors as well as decision culum for investigators comprises 9 course T. +43/1/713 40 51-0 makers of public health authorities and modules and awards graduates an academic F. +43/1/713 40 51-99 members of ethics committees throughout [email protected] title, i. e. "Academically Certified Clinical Europe, Middle East and Africa have com- www.vscr.at Research Leaders". This programme is in the pleted their postgraduate education in the progress of being extended towards a master area of clinical research at the VSCR. degree which will be launched end of 2006. The VSCR acts as a mediating institution bet- In order to compensate for the lack of inter- ween all interested parties including acade- nationally binding guide-lines for the edu- mia, industry, the public sector and society. cation of clinical researchers the VSCR's As a networking centre, the VSCR promotes mission aims at: an international interdisciplinary exchange ❚ Setting up a comprehensive education for in the biotechnological research field and clinical researchers and for experts invol- cooperates trustfully with its partner-univer- ved in clinical studies sities to guarantee that the state-of-the-art ❚ Educating decision-makers within health education is based on academically recog- care systems who must assure that the nized knowledge and. This cooperation is application of the research results is opti- the foundation of all educational activities mized and follows the principles of evi- undertaken by the VSCR. dence-based medicine The international board of teachers consists ❚ Obtaining international recognition of this of representatives of the mentioned univer- education from universities and authorities sities as well as of leading experts of the rele- ❚ Supporting clinical research experts from vant fields of expertise. The VSCR has step- developing regions by way of scholarships ped into a vacuum-clinical research that is to open these regions for clinical research not covered in the majority of the academic done according to international standards❚

32 austriantrade.org 116/2006 AUSTRIAEXPORT Bioprocessing

Virus & Prion Safety Testing Virus and Prion Removal Studies Retrovirus testing Viral Safety Consultancy Services

ViruSure GmbH of existing tests in modified formats. Technolo- Quality is not Coincidence! gically, ViruSure aims to remain at the fore- front of virus and prion safety testing through: ViruSure is an Austrian company with the ❚ a commitment of resources to research and goal to become a world leader in contract development efforts in new tests and tech- virus and prion safety testing. We have a nologies ❚ actively monitoring scientific and strong commitment to customer service and regulatory developments in virus and prion ViruSure GmbH ❚ quality, and have established the company Veterinärplatz 1 testing discussions with customers to fully strategy and credo to help us achieve this A-1210 Vienna understand any potential adventitious agent goal. This includes: T. +43/1/25077 5960 risks, and ensuring that the most appropria- An Experienced Management Team F. +43/1/25077 5961 te technologies are applied to address poten- Developing an effective pathogen safety tes- Andy Bailey tial risks ting program has always required significant [email protected] investment of time and resources. This is a www.virusure.com Technologies available include: challenge difficult to achieve without expe- ❚ Virus or prion removal and inactivation rience. At ViruSure we seek to maximise the studies ❚ Quantitative real-time viral PCR available experience through the selection of assays ❚ Retrovirus assays (molecular and cell management and Supervisory Board mem- culture based) ❚ Cell culture based assays bers ensuring that such experience is available. general virus assays ❚ In vivo tests for adventi- A Commitment to Quality and Customer tious agents ❚ Prion in vitro and in vivo tests Service Based within the Vienna University of At ViruSure, our customers come first, and Veterinary Medicine, Austria, ViruSure has ensuring that we deliver a quality service strong alliances with various departments comes at the top of our list of priorities. From offering expertise in animal based virus tes- initial contact through development of a stra- ting as well as cell culture based assays. We tegy and implementation, a strong emphasis also have a strong link with the laboratory of on quality is present throughout. A quality Prof. Bob Rohwer (Baltimore, Maryland, US), service requires that staff are first aware of a reknowned expert in prion testing, and the standards that ViruSure sets with respect Prof. Rohwer serves as a Scientific Advisor to customer service and quality. We therefore for ViruSure. place a strong emphasis on staff training and communication of our strategies. To take advantage of our friendly and profes- Technological Innovation sional service, please contact us through our Developing the right strategy may require the In vivo and in vitro virus tests website at www.virusure.com, or via email: development of new tests, or the application [email protected]. ❚

116/2006 austriantrade.org 33 AUSTRIAEXPORT Bioprocessing

Consulting Process Design Engineering Technology

The Bioprocess Company VOGELBUSCH's range of services for the biopharma industry focuses on fermentation with cell cultures with and without carrier, VOGELBUSCH – 85 years of as well as microbiological fermentations. unrivalled excellence in Special stirring systems, an experienced, reli- bioprocess technology able choice of components and profound know-how in sterile technology are the opti- VOGELBUSCH GmbH mal pre-conditions to ensure flawless long- Blechturmgasse 11 A-1051 Vienna term functioning of fermentation processes. Since 1921, the name VOGELBUSCH has T. +43/1/546 61-0 The company's complete product solution been synonymous for the engineering and F. +43/1/545 29 79 includes the reprocessing of the fermenta- construction of industrial plants using bio- Katharina Harlander tion products using the required utility faci- technological processes. [email protected] lities. VOGELBUSCH provides advanced con- The company's activities focus on technolo- www.vogelbusch.com cepts for all common downstream processes gies for the sugar, starch and food industries, and the utilities typically used in the phar- and on plants and facility components for maceutical industry. the pharmaceutical industry. VOGELBUSCH Vogelbusch’s expert team of specialized tech- provides bioprocess design, consultancy and nologists, biologists, chemists and engineers contracting services, including scale-up and has gained an international reputation for automation, based on client processes as well flawless technology and expertise in biopro- as on proprietary technology and apparatus cesses. The Vienna headquarters employ a development. workforce of approximately 100 employees. The company is a centre of excellence for the Research and development is conducted in key biotechnological tasks of fermentation, own laboratories and technological centres. separation, distillation and evaporation, and With headquarters in Vienna and subsidia- offers a wide range of proprietary technolo- ries in Houston, Texas and Hong Kong, gies for the industrial production of biocom- VOGELBUSCH can provide professional cus- modities, such as tomer services across the world ranging from initial feasibility studies to turnkey installa- ❚ Alcohol (bioethanol, industrial alcohol, tion of production plants. Reference projects beverage alcohol) throughout the world are proof of above ❚ Yeast (baker’s yeast, fodder yeast) state-of-the-art technologies. Innovative and ❚ Vinegar Technology revolves around environmentally responsible process designs ❚ Organic acids (citric acid, gluconic acid) knowledge - which means people. have contributed significantly to the success ❚ Glucose and HFS (High Fructose Syrup) of VOGELBUSCH plants. ❚

34 austriantrade.org 116/2006 AUSTRIAEXPORT Suppliers

Suppliers Animal nutrition

Biomin – the natural way Biomin is one of the key players in the international feed additive business Biomin GmbH Industriestraße 21 A-3130 Herzogenburg Besides feed additives, the latest innovation T. +43/2782 / 803 0 Lithuania and France. As a result of Biomin´s from Biomin is a new feeding system called F. +43/2782 / 803 30 rapid expansion, the ﬁrm can offer its solu- the "Biomin VBS”. The VarioBiotic System Kurt Wegleitner tions to customers in more than 100 coun- helps customers to optimise the use of their [email protected] tries worldwide. feed additives and gives nutritional recom- www.biomin.net mendations. Today Biomin cooperates with research facilities all over the world. Most of the compa- Biomin, the company that cares for health in ny´s R&D is done at the IFA-Tulln in Austria. animal nutrition, was founded in 1983. At Constant improvements in R&D as well as a this time, the idea to support health of strictly monitored quality assurance program animals to ensure high performance was form the basis for best products for our cus- unique. tomers.

The "3 men and 1 woman show” proved to This tight cooperation with Universities and be on the right track. The company as well as IFA Tulln led to new inventions in different the product range grew fast. fields. New plant protection products were explored, which fit into the philosophy of In the nineties, Biomin started to expand Biomin to be best in quality, production, effi- worldwide, with the Mycofix Plus product cacy and for the environment. The recently series as the first biotech product in mycoto- founded company bio-ferm is specialized on xin detoxification. In Asia, Biomin started up biotechnological plant protection. The pro- offices in Malaysia, Singapore, Vietnam and duct Blossom Protect fb, based on antagonis- China, in America a sub-office was started in tic micro-organisms, is going to be registered Texas and Romer Labs, a company speciali- in the EU against fire blight, one of the most sed in mycotoxin analysis, was taken over. In devastating plant diseases. Boni Protect is a Europe, Biomin opened offices in Austria, natural way to protect spoilage of apples Hungary, Slovakia, Romania, Germany, during storage. ❚

116/2006 austriantrade.org 35 AUSTRIAEXPORT Suppliers

Viscoelastics Product Development Ophthalmology, Orthopedics, Dermatology Contract Manufacturing

CROMA-PHARMA GmbH CONTRACT MANUFACTURING - Europe's leading filler of See where innovation can take you CROMAPHARMA GmbH Cost pressures, globalization, complex pri- viscoelastics Stockerauerstraße 181 cing and regulatory environments are forcing In this high-tech age, healthcare is faced with A-2100 Korneuburg pharmaceutical and biopharmaceutical com- numerous challenges: to provide high perfor- T. +43/2262/684 68-0 panies to focus on improving operational mance systems and devices, top-quality surgi- F. +43/2262/684 68-14 efficiency. Many companies have turned to cal treatments as well as the maximum protec- Mag.pharm. Martin Prinz outsourcing as the solution. [email protected] tion. At CROMA-PHARMA we have met this While most companies recognize the strategic www.croma.at challenge with our innovative technologies importance of outsourcing, many are not rea- and product design, which ultimately improve ping its potential benefits. A centralized the quality of life for patients, makes surgical management structure is the key to making treatment easier for physician as well as for the most of contract manufacturing relation- personnel. The power of innovation has ena- ships and helps create consistency across the bled us to meet this challenge: to fullfill our company. Maximize your contract manufac- social responsibility – to provide the best and turing relationships! the safest viscoelastics and surgical fluids. Our products and services are a sum of innovation, STRATEGIC PARTNERSHIPS - knowledge and experience. Life needs safety, Mutually beneficial partnerships are a key we recognize our responsibility. Our success is ingredient in CROMA-PHARMA´s growth based on innovative ideas, state-of-the art tech- The CROMA-PHARMA organisation is based nologies and know-how to develop and manu- on alliances with its customers and their con- facture pharmaceutical systems such as sterile fidence in our line of products. That is why syringes filled with viscoelastic solutions. we have formed close links with research organisations, university researchers and TECHNOLOGY - Focus on technology physicians worldwide. CROMA-PHARMA´s CROMA-PHARMA applies state-of-the-art rapid expansion is also the result of coopera- manufacturing technology. Opened in 1994, tion with various companies in the industry. the ultra modern manufacturing plant provi- This close working relationship is built on des a constant flow of products from its fully shared competence, skill transfer, mutual res- automated production line. The site´s staff of pect and open communication. We realize manufacturing and engineering specialists customer visions beyond your expectations. adhere to strict "Good Manufacturing Our philosophy is simple. A partnership with Practice” standards in the production of over a client, that’s a natural fit – then do whatever 100 different products and millions of units. it takes to show them breathtaking results. ❚

36 austriantrade.org 116/2006 AUSTRIAEXPORT Suppliers

Conceptual Design GMP-Qualiﬁcation Basic Engineering Project Management

High Tech Engineering VTU-Engineering GmbH Parkring 18 A-8074 Grambach/Graz Biotechnology needs specialized T. +43/316/4009-200 engineering know-how F. +43/316/4009-210 Dipl.-Ing. Robert Schwarz [email protected] www.vtu.com VTU Engineering is planning process plants ❚ Uncompromising orientation towards for the pharmaceuticals, biotechnology and the customer’s benefit. chemicals sectors of industry. Our activities In the end, the aim of all planning activities focus on process engineering and on com- is the production of the desired product on plete project management - from the crea- an industrial scale. The extent and the pro- tion of a concept up to final commissioning. fundity of plant engineering are measured For the pharmaceuticals industry we also by its quality and cost. Timely and local perform qualification and validation services flexibility of application and frictionless in accordance with cGMP, including the pro- cooperation with our customer’s technicians vision of support during inspections and or engineering partner are self-evident. audits. We have locations in Austria (Gram- bach/Graz, Linz, Vienna, Kundl), Germany ❚ Highly qualified employees (Frankfurt, Rheinbach/Bonn) and Italy (Bol- After having graduated at a University of zano). Furthermore we are highly flexible Technology or an Advanced Technical and willingly work at our customer’s sites. College, our carefully chosen technicians (currently approx. 80 process engineers, che- Our costumers are medium-sized companies mical engineers and bio engineers) receive as well as big players like Boehringer Ingel- continuous further training by attending spe- heim, Degussa, DSM, Roche Diagnostics, cific courses and seminars. In addition, our Sandoz or Sanofi-Aventis. knowledge management system secures that know-how is exchanged efficiently and that The success of VTU-Engineering is based on Perfect solutions by a perfect team. internal technical expertise is available two aspects: without delay. ❚

116/2006 austriantrade.org 37 AUSTRIAEXPORT > LISTING

55pharma Drug Discovery & Development AG Apeiron Biologics Forschungs- und Entwicklungs T. +43/5446/2061 [email protected] Palais Palffy GmbH F. +43/5446/2061 85 www.biopure.at A-1010 Vienna Brunner Strasse 59 [email protected] Diagnostics, page 21 T. +43/1/219890 040 A-1230 Vienna www.arlbergapotheke.com F. +43/1/219890 1 T. +43/1/865 65 77 BIOS BIOENERGIESYSTEME GmbH [email protected] F. +43/1/865 65 77-9280 BASF Österreich GmbH Inffeldgasse 21b www.55pharma.com [email protected] Kolingasse 12 A-8010 Graz www.apeiron-biologics.com A-1090 Vienna T. +43/316/481 300 27 Research and Development, page 24 T. +43/1/878 90 0 F. +43/316/481 3004 A F. +43/1/878 90 120 [email protected] Apomedica pharmazeutische Produkte GmbH [email protected] www.bios-bioenergy.at Roseggerkai 3 www.basf.at A-8010 Graz Aesca Pharma GmbH Biotec Systems Krems GmbH Badener Straße 23 T. +43/316/823533 BAXTER AG Bio Science Vienna F. +43/316/823533 52 Magnesitstraße 1 A-2514 Traiskirchen Industriestrasse 67 A-3500 Krems T. +43/2252/502 0 [email protected] A-1221 Vienna www.apomedica.com T. +43/2732/82 699 0 F. +43/2252/54294 T. +43/1/20 100-0 F. +43/2732/82 699 15 [email protected] F. +43/1/20 100-533 Applera Austria Handels GmbH [email protected] www.aesca.at [email protected] Liebermannstraße A01 303 www.biotec-systems.at www.baxter.at AFFIRIS Forschungs- und Entwicklungs GmbH A-2345 Brunn/Gebirge T. +43/1/8673575 0 Biotechnology Consulting Campus Vienna Biocenter 2 Bayer Austria GesmbH A-1030 Vienna F. +43/1/8673575 11 Wilhelminenstraße 95(BLOCK C)/17 [email protected] Lerchenfelder Gürtel 9–11 A-1160 Vienna T. +43/1/7981575 10 A-1164 Vienna F. +43/1/7981575 11 www.appliedbiosystems.com T. +43/1/4810987 T. +43/1/711 46 0 F. +43/1/664 1477280 [email protected] F. +43/1/711 46 14 www.affiris.com Ars Arthro Biotechnologie GmbH [email protected] Magnesistraße 1 www.bayer.at www.biotechconsulting.at A-3500 Krems Agneter PharmaConsulting GmbH BDF Beiersdorf GesmbH Mariahilfer Strasse 71/15 T. +43/2732/76954 Biovertis - Information Driven Drug Design AG F. +43/2732/76954 50 Laxenburgerstraße 151 Campus Vienna Biocenter 6 A-1060 Vienna A-1100 Vienna [email protected] A-1030 Vienna T. +43/1/5264244 T. +43/1/614000 317 www.ars-arthro-ag.com T. +43/1/798 93 03 F. +43/1/5264366 F. +43/1/61400 300 F. +43/1/789 93 03-400 [email protected] [email protected] Ash Dec Umwelt AG [email protected] www.pharmaconsulting.at www.beiersdorf.at Pharmaceuticals page 16 Donaufelder Straße 101/4/5 http://biovertis.com A-1210 Vienna Bender MedSystems GmbH AlcaSynn Pharmaceuticals GmbH T. +43/1/7344640 F. +43/1/7344640 20 Campus Vienna Biocenter 2 Biovest Consulting GmbH Life Science Center, Mitterweg 24 [email protected] Lerchenfelderstr. 88–90/22 A-6020 Innsbruck A-1030 Vienna www.ashdec.com T. +43/1/796 4040 106 A-1080 Vienna T. +43/512/282 283 15 T. +43/1/9233048 F. +43/512/282 283 44 F. +43/1/796 4040 400 Astellas Pharma Ges.m.b.H. F. +43/1/9905168 [email protected] [email protected] Linzerstrasse 221 E 02 www.bendermedsystems.com [email protected] www.alcasynn.com A-1140 Vienna T. +43/1/8772668 0 Biozym GmbH Alfa Laval Mid Europe GmbH Biodesign Consulting engineering GmbH F. +43/1/8771636 An der Scheibenwiese 1/2/9 Biochemiestraße 10 IZ NÖ Süd Straße 2 / M7 / 1 [email protected] A-6250 Tirol A-2355 Wr. Neudorf A-1160 Vienna www.astellas.at T. +43/1/9111344 T. +43/5338/200 0 T. +43/2236/682 0 F. +43/5338/200 460 F. +43/2236/65940 F. +43/1/9111344 Aureon Biosystems GmbH heinrich.scherfl[email protected] [email protected] Simmeringer Hauptstraße 24 www.alfalaval.com BioDevelops Pharma Entwicklung GmbH A-1110 Vienna Brunner Straße 59/59 Bittner Pharma - Richard Bittner AG, Büro Vienna T. +43/1/740 40 350 A-1230 Vienna Kärntner Ring 11–13 Algavital Vertriebs GmbH F. +43/1/740 40 359 Römerstraße 10 T. +43/1/710661 6 A-1010 Vienna [email protected] F. +43/1/710661 4 T. +43/1/503 09 72 A-2424 Zurndorf www.aureonbio.com T. +43/2147/7000 200 [email protected] F. +43/1/503 09 7240 F. +43/2147/7000 203 www.biodevelops.com [email protected] Aurora Feinchemie GmbH, www.bittner-pharma.com [email protected] Kutyrev Alexandre, Dr. www.algavital.com Reininghausstraße 49 Biodiesel Kärnten GmbH A-8020 Graz Industriestrasse 29 BMT Medizinische Forschung und Entwicklung GmbH ALK Abello Allergie-Service GmbH T. +43/316/58 67 38 A-9601 Arnoldstein Brunnerstraße 59/5 Bäckermühlweg 59 F. +43/316/58 47 44 T. +43/4255/908 12 21 A-1235 Vienna A-4030 Linz [email protected] F. +43/4255/908 12 22 T. +43/1/867 36 91 T. +43/732/385372 0 www.aurora-feinchemie.com [email protected] F. +43/1/867 36 94 F. +43/732/385372 77 www.biodiesel-kaernten.com [email protected] [email protected] Austrian Energy & Environment AG www.bmt-research.at www.alk-abello.at Waagner-Biro-Platz 1 Bioenergetik Rechberger KEG A-8074 Raaba Löwengasse 40/2/3 Boehringer Ingelheim Austria GmbH Alvetra u.Werfft AG T. +43/316/501 0 A-1030 Vienna Dr. Boehringer-Gasse 5–11 Boltzmanngasse 11 F. +43/316/501 482 T. +43/1/966 9663 A-1121 Vienna A-1091 Vienna [email protected] F. +43/1/966 9662 T. +43/1/80105-2141 T. +43/1/3191456 0 www.aee.co.at [email protected] F. +43/1/80105-2440 F. +43/1/3191456 44 www.bioenergetik.co.at [email protected] [email protected] Austrianova Biotechnologie GmbH www.boehringer-ingelheim.at www.alvetrawerfft.at Veterinärpl. 1, Gebäude AC-2. Stock biolution Grünert & Co KEG Pharmaceuticals, page 17 A-1210 Vienna Stutterheimstrasse 16-18 Amynon BioTech GmbH T. +43/1/25077 2601 A-1150 Vienna Boehringer Ingelheim Pharma GesmbH Innrain 66/III F. +43/1/25077 2690 T. +43/1/7869595 Dr. Boehringer Gasse 5–11 A-6020 Innsbruck [email protected] F. +43/1/7869595 20 A-1121 Vienna T. +43/512/50425 767 www.austrianova.com [email protected] F. +43/512/50425 852 T. +43/1/801 05 0 barbara.fi[email protected] F. +43/1/804 08 23 Austroplant-Arzneimittel Gesellschaft m.b.H. BIOMAY AG [email protected] www.amynon.com Richard-Strauss-Strasse 13 Lazarettgasse 19 Top 1 www.boehringer-ingelheim.at Research and Development, page 23 A-1232 Vienna A-1090 Vienna T. +43/1/61626440 T. +43/1/796 62 96 100 Brady C. An der Grub Bio Research GmbH F. +43/1/616264418 F. +43/1/796 62 96 111 Gerichtsberg 28, An der Grub [email protected] Hörlgasse 5 [email protected] A-1090 Vienna A-2572 Kaumberg www.austroplant.at www.biomay.com T. +43/2765/597 0 T. +43/1/3106960 F. +43/2765/597 3 Aventis Pasteur MSD GmbH F. +43/1/3106960 27 Biomechanische Forschungs-Gesellschaft m.b.H. [email protected] Lemböckgasse 49/2/Top E 5–2 Rechte Viennazeile 5/2 Angewandte Biotechnologie GmbH www.brady.at A-1230 Vienna A-1043 Vienna Hellbrunnerstraße 34 T. +43/1/61 04 70 T. +43/1/586 64 46 0 A-5020 Salzburg F. +43/1/61 67 97 8 Bunge Austria GmbH F. +43/1/586 64 46-30 T. +43/662/639 61 0 georgine.flaschner@sanofipasteur.com Industriegelände West 3 [email protected] www.aventis-pasteur-msd.com A-2460 Bruck an der Leitha www.bmf.at Anstalt zur gewerblichen Produktion von Heilmitteln T. +43/2162/606 0 und Arzneiwaren GmbH Aventis Pharma GmbH F. +43/2162/606 18 BIOMEDICA Medizinprodukte GmbH & CO KG Simmeringer Hauptstraße 24 Leonardbernsteinstraße 10 [email protected] Divischgasse 4 A-1110 Vienna A-1220 Vienna www.bunge.com T. +43/1/740 40 5769 T. +43/1/801 85 0 A-1210 Vienna F. +43/1/740 40 5770 F. +43/1/801 85 8000 T. +43/1/291 07 11 [email protected] service.at@sanofi-aventis.com F. +43/1/291 07 13 www.agepha.com www.sanofi-aventis.com [email protected] C www.biomedica.co.at C4 Holding AG Anton Paar GmbH Axon Neuroscience Forschungs- und Anton Paar Strasse 20 EntwicklungsgmbH Biomin GmbH Tuchlauben 8 A-8054 Graz-Strassgang Rennweg 95 B Industriestrasse 21 A-1010 Vienna T. +43/316/257 0 A-1030 Vienna A-3130 Herzogenburg T. +43/1/5327888 F. +43/316/257 257 T. +43/1/7966898 T. +43/2783/803 0 F. +43/1/5327888 11 [email protected] F. +43/1/7966898 20 F. +43/2783/803 30 [email protected] www.anton-paar.com [email protected] [email protected] www.c4group.at www.axon-neuroscience.at/ www.biomin.net AOP Orphan Pharmaceuticals AG Suppliers, page 35 Carl Zeiss GmbH Wilhelminenstrasse 91/II f/B4 Modecenterstraße 16 A-1160 Vienna Biopure Referenzsubstanzen GmbH A-1030 Vienna T. +43/1/5037244 B Technopark 1 T. +43/1/795 18 0 F. +43/1/5037244 61 Bano Mag. Josef Chem.-Pharm. Präparate A-3430 Tulln F. +43/1/795 18 900 [email protected] Im Gries 22 T. +43/2272/615 33 20 [email protected] www.aoporphan.com A-6580 St. Anton am Arlberg F. +43/2272/615 33 211 www.zeiss.at

38 austriantrade.org 116/2006 AUSTRIAEXPORT > LISTING

CeMM - Forschungszentrum für molekulare Medizin gcp gamma capital partners Beratungs- & [email protected], GmbH Beteiligungs GmbH www.human.technology.at Lazaretgasse19 E Marokkanergasse 22/7 page 11 A-1090 Vienna EBEWE Pharma GmbH Nfg.KG A-1030 Vienna T. +43/1/401 60 70 01 1 Mondseestraße 11 T. +43/1/513 10 72 F. +43/1/401 60 97 00 00 A-4866 Unterach am Attersee [email protected] I [email protected] T. +43/7665/8123 0 www.gamma-capital.com www.cemm.at F. +43/7665/8123 11 I-Med Laboratory of Tumor Immunology ; Children's [email protected] Gebro Pharma GmbH Cancer Research Institute Chemgineering Planung GmbH www.ebewe.com Bahnhofbichl 11 Kinderspitalgasse 6 Perfektastraße 45 A-6391 Fieberbrunn A-1090 Vienna A-1230 Vienna EccoCell Biotechnologie GmbH T. +43/5354/53000 T. +43/1/401 70-0 T. +43/1/2557413 Körblergasse 42 (Sanatorium Hansa) F. +43/5354/5300710 F. +43/1/408 7230 F. +43/1/2557413 20 A-8010 Graz [email protected] [email protected] T. +43/316/722866 13 www.gebro.com I.T.S. Implantat-Technologie-Systeme GmbH www.chemgineering.com F. +43/316/722866 99 Autal 28 [email protected] GenoSense Diagnostics GmbH A-8301 Laßnitzhöhe T. +43/316/211210 Chemomedica Medizintechnik u. Arzneimittel www.eccocell.com Rennweg 95 B Ebene 5 VertriebsgmbH A-1030 Vienna F. +43/316/2112120 Wipplingerstraße 19 T. +43/1/7966572 90 [email protected] ECOWORK LABORATORIES Consulting GmbH www.its-implant.com A-1010 Vienna Brehmstraße 14 A F. +43/1/2530253 191 T. +43/1/53326660 [email protected] A-1110 Vienna IGENEON Krebs-Immuntherapie Forschungs- und F. +43/1/535330658 T. +43/1/606 45 95 www.genosense.com [email protected] Entwicklungs-GmbH F. +43/1/606 45 95 15 Brunner Strasse 69, Objekt 3 www.chemomedica.at [email protected] Gepa-Med Medizintechnik GmbH Sprengersteig 4 A-1230 Vienna www.ecowork.at T. +43/1/90250 0 Chepharin Chemisch- pharmazeutische Industrie A-1160 Vienna F. +43/1/90250 901 GmbH Eichenauer`s Kräuterparadies T. +43/1/4896353 F. +43/1/4896353 43 [email protected] Flatschacher Straße 57 Eichendorffstrasse 58 www.igeneon.com A-9020 Klagenfurt A-4020 Linz [email protected] www.gepa.at T. +43/463/316 35 0 [email protected] igor - Institut für Gewebe und Organrekonstruktion F. +43/463/316 35 5 Ges.m.b.H. [email protected] Eli Lilly GesmbH Germania Pharmazeutika GesmbH Schuselkagasse 8 Bernadingasse 12 www.montavit.com Barichgasse 40–42 A-4600 Wels A-1030 Vienna A-1150 Vienna T. +43/1/982 33 99 T. +43/7242/4412820 CIS Clinical Investigation Support Pharmaforschung T. +43/1/71178-0 F. +43/7242/4412812 Gesellschaft m.b.H. F. +43/1/71178-264 F. +43/1/982 33 99 24 [email protected] [email protected] Kaiserstrasse 43 [email protected] www.igor.at A-1070 Vienna www.lilly.at Gerot Pharmazeutika GmbH T. +43/1/523 40 15 Immodal Pharmaka GesmbH Arnethgasse 3 F. +43/1/523 40 15-99 emergentec biodevelopment GmbH Bundesstraße 44 A-1160 Vienna [email protected] Rathausstrasse 5/3 A-6111 Volders T. +43/1/485 35 05 0 www.cis-qa.com A-1010 Vienna T. +43/5224/57678 F. +43/1/485 77 73 Research and Development, page 25 T. +43/1/4034966 F. +43/5224/57646 [email protected] F. +43/1/403 49 66 [email protected] www.gerot.at CNSystems Medizintechnik GmbH [email protected] www.immodal.com Reininghausstrasse 13 www.emergentec.com A-8020 Graz GLOBOPHARM Pharmazeutische Produktions- und INGENETIX Vertriebs GmbH Handels GesmbH T. +43/316/723456 EUCODIS GmbH Mariahilferstraße 5/8 Bräunlichg.40–42 F. +43/316/723456 2 Brunner Strasse 59 A-1060 Vienna A-2700 Wr. Neustadt [email protected] A-1230 Vienna T. +43/1/585 80 91 T. +43/1/8031727 373 www.cnsystems.at T. +43/1/866 34 9240 F. +43/1/585 80 92 F. +43/1/8031727 372 F. +43/1/866 34 449 [email protected] CoaChrom Diagnostica GmbH [email protected] www.ingenetix.com [email protected], [email protected] www.globopharm.at Stolzenthalergasse 6 www.eucodis.com A-1080 Vienna Innovacell Biotechnologie GmbH Research and Development, page 26 Green Hills Biotechnology Research Development T. +43/1/6999797 0 Mitterweg 24 Trade GmbH F. +43/1/6991897 A-6020 Innsbruck Ezinger Ing. August Biochemische Erzeugnisse Gersthoferstr. 29–31 [email protected] T. +43/512/573680 Unterpramau 1 A-1180 Vienna www.coachrom.com A-4775 Taufkirchen an der Pram F. +43/512/573680 5 T. +43/1/3199670 [email protected] T. +43/7719/7517 F. +43/1/3199670 30 CROMA PHARMA GmbH www.innovacell.at F. +43/7719/8839 [email protected] Stockerauerstrasse 181 [email protected] www.greenhillsbiotech.com INOVIA Hutzinger GmbH & Co KG A-2100 Korneuburg www.vitamix.at Edtholz 21 T. +43/2262/684 68 0 A-4600 Wels F. +43/2262/684 68 14 T. +43/7242/350159 0 [email protected] F H F. +43/7242/350159 4 www.croma.com [email protected] Suppliers, page 36 HÄMOSAN Life Science Services GmbH Faromed GmbH Neudorf 41 www.inovia.at Johann Strauß-Gasse 7/5 A-8262 Ilz A-1040 Vienna T. +43/3385/8117 Insight Instruments Dr. Dieter Kropfreiter D T. +43/1/50574740 F. +43/3385/8117 44 Steglandweg 5 F. +43/1/505747474 [email protected] A-5400 Hallein Donau Chemie AG [email protected] www.haemosan.com T. +43/6245/71149 Am Heumarkt 10 F. +43/6245/70466 A-1030 Vienna Ferdinand Menzl Medizintechnik Harichem Chemische Produkte GmbH [email protected] T. +43/1/71147 0 Donaufelderstrasse 189 Bayergasse 1/7 www.insight.co.at F. +43/1/71147 309 A-1220 Vienna A-1030 Vienna [email protected] T. +43/1/255 89 60 T. +43/1/710 47 47 INSILICO Software GmbH www.donau-chemie.com F. +43/1/255 89 60 60 F. +43/1/710 47 07 Donau-City-Straße 1, Gate 3/4.Stock [email protected] [email protected] A-1220 Vienna Doskar Martin Mag. www.menzl.com T. +43/1/2051224 Schottenring 14 Hauser Paul Herba Apotheken AG F. +43/1/2051224 12 A-1013 Vienna Fibrex Medical Research & Development GmbH Flatschacher Straße 57 [email protected] T. +43/1/5353724 23 Brunnerstr. 59 A-9020 Klagenfurt www.insilico.at F. +43/1/5353724 24 A-1235 Vienna T. +43/463/38300 [email protected] T. +43/1/86634-9270 F. +43/463/3830 9241 Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) www.doskar.at F. +43/1/86634-9279 [email protected] Dr. Bohr-Gasse 7 rainer.henning@fibrexmedical.com www.herba-chemosan.at Dr. A. & L. Schmidgall KG www.fibrexmedical.com A-1030 Vienna T. +43/1/79730 456 Wolfganggasse 45–47 Research and Development, page 27 Henkel Central Eastern Europe GmbH A-1120 Vienna F. +43/1/79730 459 Erdbergstraße 29 www.imba.oeaw.ac.at T. +43/1/811 58 0 Forschungsinstitut für molekulare Pathologie GmbH A-1030 Vienna F. +43/1/811 58 7 Dr. Bohrgasse 7 T. +43/1/711 04 0 [email protected] A-1030 Vienna Inte:Ligand Software-Entwicklungs und Consulting F. +43/1/711 04 2523 GmbH www.schmidgall.at T. +43/1/797 30 0 [email protected] F. +43/1/798 71 53 Clemens Maria Hofbauer-G. 6 www.henkel.at A-2344 Maria Enzersdorf Dr. Kolassa & Merz GesmbH [email protected] T. +43/2236/650 374 83 47 Gastgebgasse 5-13 www.imp.univie.ac.at HITT-health information technolgies tirol F. +43/2236/650 374 83 47 2 A-1230 Vienna Leopoldstraße 1 [email protected] T. +43/1/8691604 0 A-6020 Innsbruck www.inteligand.com F. +43/1/8691604 18 G T. +43/512/576523 [email protected] F. +43/512/576523 70 INTERCELL AG www.merz.co.at G.L. Pharma GmbH [email protected] Campus Vienna Biocenter 6 Schloßplatz 1 www.hitt.at A-1030 Vienna Dr. Oliver Dinstl A-8502 Lannach T. +43/1/20620 0 Telekygasse 15 T. +43/3136/82577 HL Dr. Hans Loibner Bioscience Research GmbH F. +43/1/20620 800 A-1190 Vienna F. +43/3136/81563 Brunner Straße 59 [email protected] [email protected] [email protected] A-1230 Vienna www.intercell.com www.dinstl.net www.lannacher.at T. +43/1/888 76 15 F. +43/1/888 76 15 Ionimed Analytik Ges. m.b.H. DSM Fine Chemicals Austria Nfg GmbH & Co KG GAT Formulation GmbH [email protected] Technikerstraße 21a St.Peter Straße 25 Gewerbezone 1 A-6020 Innsbruck A-4020 Linz, Donau A-2490 Ebenfurth Human.technology Styria GmbH T. +43/512/507-4810 T. +43/732/6916 0 T. +43/2624/53922 Reininghausstrasse 13 F. +43/512/507-9818 F. +43/732/6916 3890 F. +43/2624/53922 38 A-8020 Graz [email protected] [email protected] [email protected] T. +43/316/587016-0 www.ionimed.at www.dsmfinechemicals.com www.gat-formulation.com F. +43/316/587016-16 Research and Development, page 28

116/2006 austriantrade.org 39 AUSTRIAEXPORT > LISTING

F. +43/662/87 21 27 T. +43/2262/68409 0 F. +43/5212/2204 15 [email protected] F. +43/2262/68409 15 [email protected] J www.lifecrystal.at [email protected] www.ichthyol.at JSW-Research Forschungslabor GmbH Rankengasse 28a Mycosafe Diagnostics GmbH A-8020 Graz Veterinaerplatz 1, Campus University of Veterinary T. +43/316/76 51 14-22 M Medicine Vienna P F. +43/316/76 51 14 4 Mayrhofer Pharmalogistik GmbH A-1210 Vienna P.P.M. Energie aus nachwachsenden Rohstoffen [email protected]@jswresearch.com Dr. Karl Lueger-Ring 6 T. +43/1/250 77-2150 GmbH www.jswresearch.com A-1010 Vienna F. +43/1/250 77-2190 Mühlengasse 5 Research and Development, page 29 T. +43/5/997726 0 [email protected] A-3041 Asperhofen F. +43/5/997726 615 www.mycosafe.at T. +43/2772/584 11 Pharmaceuticals, page 18 Jungbunzlauer Austria AG [email protected] F. +43/2772/519 92 Schwarzenbergplatz 16 www.mayrhofer.com [email protected] A-1010 Vienna www.ppm-biodiesel.com T. +43/1/50200 Med-El Elektromedizinische Geräte GmbH N F. +43/1/50200 8 Fürstenweg 77a PAA Laboratories GmbH [email protected] A-6020 Innsbruck Nabriva Therapeutics Forschungs GmbH Haidmannweg 9 Brunnerstraße 59 www.jungbunzlauer.com T. +43/512/288889 A-4061 Pasching A-1235 Vienna F. +43/512/293381 T. +43/7229/64865 T. +43/1/86659 [email protected] F. +43/7229/64866 www.medel.com F. +43/1/866 59-785 K [email protected] [email protected] www.paa.com Kendro Laboratory Products GesmbH Medimplant Medizinisch-Technische Geräte GesmbH www.nabriva.com Wiegelestraße 4 Laudongasse 10 Nano S Biotechnologie GmbH Pelias Biotechnologies GmbH A-1230 Vienna A-1080 Vienna Dannebergplatz 16/2 T. +43/1/80140 0 T. +43/1/4086848 Gregor Mendelstrasse 33, A-1180 Vienna A-1030 Vienna F. +43/1/80140 40 F. +43/1/4030405 T. +43/1/7180326 326 [email protected] [email protected] T. +43/1/47654 2219 F. +43/1/47654 2218 F. +43/1/7180326 800 www.thermo.com www.pelias.com Medizinische Universität Graz [email protected] Universitätsplatz 3 www.nano-s.com Kompetenzzentrum Medizin GmbH Pfizer Corporation Austria GmbH Leopoldstraße 1/3 A-8010 Graz Neuberger Research Floridsdorfer Hauptstraße 1 A-6020 Innsbruck T. +43/3182/380 0 Praterstraße 43/3/15 A-1210 Vienna T. +43/512/576526 [email protected] A-1020 Vienna T. +43/1/521 150 F. +43/512/576526-4320 www.meduni-graz.at T. +43/1/7869390 F. +43/1/526 91 32 [email protected] F. +43/1/7869391 pfizer.austria@pfizer.com www.kmt.at MELASAN Produktions- und Vertriebsges.m.b.H. [email protected] www.pfizer.at Research and Development, page 30 Nordstraße 1 A-5301 Eugendorf www.neubergerresearch.com Kplus ECHEM T. +43/6225/28405 Pharmazeutische Fabrik Montavit GmbH Novartis Institutes for BioMedical Research GmbH & Viktor Kaplan Straße 2 F. +43/6225/28405 30 Salzbergstraße 96 Co KG A-2700 Wr. Neustadt [email protected] A-6067 Absam www.melasan.com Brunner Straße 59 T. +43/5223/579 26 0 T. +43/2622/22266 A-1235 Vienna [email protected] F. +43/5223/579 26 11 Merck GmbH T. +43/1/866 34-0 [email protected] F. +43/1/866 34-285 Kühne Christian Dr. Dipl.-Ing. Zimbagasse 5 www.montavit.com A-1147 Vienna [email protected] Zeinlhofergasse 6/18 www.novartis.at A-1050 Vienna T. +43/1/576000 Pharmonta Dr. Fischer GmbH F. +43/1/57773370 Montanastraße 7 T. +43/1/581 34 62 NOVA TECHnical Research GmbH [email protected] A-8112 Gratwein Wohllebengasse 10/7 Kwizda Pharma GmbH www.merck.at T. +43/3124/51368-0 A-1040 Vienna F. +43/3124/51368-21 Effingergasse 21 T. +43/1/503 16 89 Merck GmbH Werk Spittal [email protected] A-1160 Vienna F. +43/1/503 53 26 T. +43/5/99 77 30 0 Hößlgasse 20 [email protected] Philips Austria GmbH, Werk Klagenfurt F. +43/5/99 77 30 320 A-9800 Spittal/Drau www.novatechresearch.com [email protected] T. +43/4762/5151-0 Koningsbergerstraße 11 A-9020 Klagenfurt www.kwizda.at F. +43/4762/5151 22 NOWICKY PHARMA [email protected] Margaretenstrasse 7 T. +43/463/3866 www.merck.at A-1040 Vienna F. +43/463/3866 888 L T. +43/1/5861223 [email protected] Metochem Pharma GesmbH F. +43/1/5868994 www.philips.at Labor f. Immunologie u. Immuntherapie der Jochen Rindt Straße 23 [email protected] Universitätsklinik f. Urologie, Medizinische A-1239 Vienna www.ukrin.com piCHEM Forschungs-und Entwicklungs GmbH Universität Innsbruck T. +43/1/6168425 0 Pharmaceuticals, page 19 Kahngasse 20 Anichstraße 35 F. +43/1/6168425 10 A-8045 Graz-Andritz A-6020 Innsbruck [email protected] Nycomed Austria GmbH T. +43/316/681 71 10 T. +43/5/05 04 24867 www.apo-shop.at St.Peter Straße 25 F. +43/316/681 71 14 F. +43/5/05 04 24817 A-4021 Linz, Donau [email protected] [email protected] Michael Weinzierl GmbH T. +43/732/69 19 0 www.pichem.at www.immuntherapie-ibk.at Europaring F 12/401 F. +43/732/65 55 68 A-2345 Brunn am Gebirge [email protected] Pioneer Hi-Bred Services GmbH LACTOSAN, Starterkulturen Gesellschaft m.b.H. & Co. T. +43/2236/31 22 31 www.nycomed.at Pioneerstraße Industriegelände KG F. +43/2236/31 22 32 A-7111 Parndorf Industrie- und Gewerbepark [email protected] T. +43/2166/2525 0 A-8605 Kapfenberg www.weinzierl.at F. +43/2166/2525 62 T. +43/3862/32602 O [email protected] F. +43/3862/32602 4 Michael Zamponi Obwaller Forschungs- und Entwicklungs GmbH www.pioneer.com [email protected] Burgg 43 Stutterheimstraße 16-18/2/1 www.lactosan.at A-8750 Judenburg A-1150 Vienna Pirich Eberhard Dr., PR Beratung im T. +43/3572/84381 T. +43/1/890 14 11 Gesundheitswesen Lambda GmbH F. +43/3572/84357 F. +43/1/890 14 11 15 Felix Mottl-Straße 32 Industriestraße 6 [email protected] [email protected] A-1190 Vienna A-4240 Freistadt www.zamponi.at www.obwaller.com T. +43/1/3680850 T. +43/7942/75055-900 F. +43/1/3680850 3 F. +43/7942/75055-910 Molekulare Biotechnologie GmbH Octapharma Pharmazeutika Produktions GesmbH [email protected] [email protected] Mariagrünerstraße 91 Oberlaaer Straße 235 A-8043 Graz www.lambda.at A-1100 Vienna PLANTA Naturstoffe Vertriebsges.m.b.H. T. +43/316/873 84 18 Research and Development, page 31 T. +43/1/61032 0 Erlgasse 48 [email protected] F. +43/1/61032 300 A-1120 Vienna Lannacher Heilmittel GesmbH [email protected] Mr. pharm. Josef. W.Wenig, Pharm. chem. Erzeugung T. +43/1/8105366 Schloßplatz 1 www.octapharma.com F. +43/1/8105366 13 A-8502 Lannach GesmbH [email protected] T. +43/3136/82577 Van der Nuellgasse 22 onepharm Research & Development GmbH www.planta.at F. +43/3136/81563 A-1100 Vienna Gersthoferstraße 29–31 [email protected] T. +43/1/6041490 0 A-1180 Vienna Polymun Scientific Immunbiologische Forschung www.lannacher.at F. +43/1/6041490 6 [email protected] [email protected] GesmbH Nußdorfer Lände 11 Life Optics GmbH OÖ. Technologie- und Marketinggesellschaft m.b.H. A-1190 Vienna Seeböckgasse 59 Mr.Petrasch GesmbH & CO Chem.Pharm.Fabrik Hafenstraße 47–51 T. +43/1/36006 6202 A-1160 Vienna Schlachthausstraße 3 A-4020 Linz T. +43/1/478 99 10 A-6850 Dornbirn T. +43/732/7981-5005 F. +43/1/3697615 F. +43/1/478 99 11 T. +43/5572/227 29 F. +43/732/79810-5008 [email protected] [email protected] F. +43/5572/227 29 15 [email protected] www.polymun.com www.lifeoptics.com [email protected] www.ooe2010.at www.petrasch.at page 13 Porr Umwelttechnik GmbH Life Science Austria (LISA) Vienna Region Absberggasse 47 Ebendorferstraße 4 MTI Maize Technologies International GmbH Oridis Biomed Forschungs- und Entwicklungs GmbH A-1100 Vienna A-1010 Vienna Ludwig Boltzmann Straße 2 Stiftingtalstr. 3–5 T. +43/5/626 2010 T. +43/1/4000-86934 A-7100 Neusiedl A-8010 Graz F. +43/5/626 2033 F. +43/1/4000-7099 T. +43/5/9010 8170 T. +43/316/325 776 [email protected] [email protected] F. +43/5/9010 8171 F. +43/316/325 776 22 www.porr.at www.lisavr.at [email protected] [email protected] page 12 www.maizetec.com www.oridis-biomed.com ProtAffin Biotechnologie AG Impulszentrum Graz-West, Lifecrystal Gesundheitsprodukte GmbH Mucobiomer Biotechnologische Forschungs- und Österreichische Ichthyol GmbH Nunmehr KG A-8020 Graz Breitenfelderstraße 18 a Entwicklungs GmbH Maximilianshütte T. +43/316/380 53 73 A-5020 Salzburg Industriezeile 6 A-6100 Reith bei Seefeld F. +43/316/380 25 41 T. +43/662/87 21 27 A-2100 Leobendorf T. +43/5212/2204 [email protected]

40 austriantrade.org 116/2006 AUSTRIAEXPORT > LISTING • INDEX

Seeg-Südsteirische Energie u. Eiweisserzeugung Ulbing Ilse Maria Reg.Gen.mbH Neutorgasse 22 Q Pestkreuzweg 3 A-8010 Graz Z Quantas Analytics GmbH A-8480 Mureck T. +43/316/38 37 46 F. +43/316/38 37 46 Zechner Gisela Dipl.-Ing. Technopark 1 T. +43/3472/3577 0 Breitenseer Straße 49/3/4 F. +43/3472/3910 [email protected] A-3430 Tulln A-1140 Vienna [email protected] T. +43/2272/615 33 30 T. +43/1/98 54 276 F. +43/2272/615 33 311 www.seeg.at/seeg.php F. +43/1/98 31 229 [email protected] V www.biopure.at Solvay Vienna GmbH [email protected] Diagnostics, page 21 Stättermayergasse 28–30 Vana GmbH www.life-science.at Wolfgang-Schmälzl-Gasse 6 A-1150 Vienna A-1020 Vienna Quintiles GesmbH Zeta Anlagenbau GmbH T. +43/1/716880 T. +43/1/728 036 70 Guglgasse 7–9/B/OG 6 Paracelsusweg 1 F. +43/1/7102426 F. +43/1/728 0367 20 A-8144 Tobelbad A-1030 Vienna [email protected] [email protected] T. +43/1/7263010 www.solvay.com www.vana.at T. +43/3136/9010-0 F. +43/1/7263010 100 F. +43/3136/9010-0 [email protected] Spagyra KG Ph. Mr. Heinrich Sedlar Pharm.-biologi- VBC-Genomics Bioscience Research GmbH [email protected] www.quintiles.com sche Präparate Rennweg 95B www.zeta.at Marktplatz 5A A-1030 Vienna A-5082 Grödig T. +43/1/796 65 72 ZLB Behring GmbH R T. +43/6246/72370 F. +43/1/796 65 72 21 Altmannsdorferstraße 104 F. +43/6246/73165 [email protected] A-1120 Vienna rho-BeSt coating Hartstoffbeschichtungs GmbH www.vbc-genomics.com [email protected] T. +43/1/801 01 2463 Erlach 165 www.spagyra.at A-6150 Steinach am Brenner VBC Vienna Bio Center Errichtungs GmbH F. +43/1/801 01 2810 [email protected] T. +43/5272/6269 SY-LAB Geräte GmbH Rathausplatz 2 A-1010 Vienna www.zlbbehring.at F. +43/5272/6269 99 Tullnerbachstraße 61–65 [email protected] T. +43/1/4000 86172 A-3011 Neu-Purkersdorf F. +43/1/4000 7099 Zuckerforschung Tulln GmbH www.rhobest.com T. +43/2231/62252 [email protected] Josef-Reither-Straße 21–23 F. +43/2231/62193 Richter Pharma AG www.biotechregion.at A-3430 Tulln [email protected] Feldgasse 19 T. +43/2272/602402 www.sylab.com Viatris Pharma GmbH A-4600 Wels F. +43/2272/602420 T. +43/7242/4900 Liesinger Flur-Gasse 2c A-1230 Vienna [email protected] F. +43/7242/490417 www.zuckerforschung.at [email protected] T T. +43/1/86 390 0 www.richter-pharma.com F. +43/1/86 390 3161 Tecan Austria GmbH [email protected] www.viatris.com Roche Diagnostics GesmbH Untersbergstraße 1A Engelhorngasse 3 A-5082 Grödig T. +43/6246/89 33 Vienna School of Clinical Research A-1211 Vienna Kölblgasse 10, P.O. Box 109 F. +43/6246/727 70 T. +43/1/27787 0 A-1031 Vienna F. +43/1/27787 12 [email protected] T. +43/1/713 40 51-0 INDEX [email protected] www.tecan.com F. +43/1/713 40 51-99 www.roche.at [email protected] Technoclone Herstellung von Diagnostika und www.vscr.at PHARMACEUTICALS Romer Labs Diagnostic GmbH Arzneimitteln Gesellschaft m.b.H. Research and Development, page 32 Agneter PharmaConsulting GmbH, page 16 Technopark 1 Brunner Straße 59/5 Boehringer Ingelheim Austria GmbH, page 17 A-3430 Tulln A-1235 Vienna ViennaLab Labordiagnostika GmbH Fibrex Medical Research & Development GmbH, page 27 T. +43/2272/6153310 T. +43/1/863 73 0 Am Kanal 27 F. +43/2272/61533-111 F. +43/1/863 73 44 A-1110 Vienna JSW-Research Forschungslabor GmbH, page 29 [email protected] [email protected] T. +43/1/74040190 Mycosafe Diagnostics GmbH, page 18 www.romerlabs.com www.technoclone.com F. +43/1/74040199 NOWICKY PHARMA, page 19 Diagnostics, page 21 [email protected] Sanochemia Pharmazeutica AG, page 20 Technopol Krems www.viennalab.com Rösch & Handel Vorm. Gimborn & Co GmbH & Co KG Magnesitstraße 1 DIAGNOSTICS Gudrunstraße 150 A-3500 Krems ViruSure GmbH Veterinärplatz 1 A-1100 Vienna T. +43/2732/87470-230 Amynon BioTech GmbH, page 23 A-1210 Vienna T. +43/1/60414900 F. +43/2732/87470-70 Biopure Referenzsubstanzen GmbH, page 21 F. +43/1/60414906 T. +43/1/25077 5960 [email protected] Lambda GmbH, page 31 [email protected] F. +43/1/25077 5961 www.ecoplus.at/technology Quantas Analytics GmbH, page 21 www.roesch-handel.at [email protected] page 14 www.virusure.com Romer Labs Diagnostic GmbH, page 21 Bioprocessing, page 33 Sanochemia Pharmazeutika AG, page 20 Technopol Tulln vitateq biotechnology GmbH, page 22 S Technopark 1 vitateq biotechnology GmbH A-3430 Tulln Innrain 66 Salzmann Ingenieubüro GmbH T. +43/2272/61375-10 A-6020 Innsbruck RESEARCH AND DEVELOPMENT Angelika Kauffmann Straße 5 T. +43/512/504 25590 A-6900 Bregenz F. +43/2272/61375-44 Agneter PharmaConsulting GmbH, page 16 [email protected] F. +43/512/504 25599 T. +43/5574/45524 0 [email protected] Amynon BioTech GmbH, page 23 F. +43/5574/45524 29 www.ecoplus.at/technology Apeiron Biologics Forschungs- und Entwicklungs GmbH, page 14 www.vitateq.com [email protected] Diagnostics, page 22 page 24 www.salzmann-ing.at Biopure Referenzsubstanzen GmbH, page 21 ThioMatrix Forschungs- und Beratungs GmbH Vitro Plant Pﬂanzen-Biotechnologie GmbH CIS Clinical Investigation Support Pharmaforschung Unterer Platz 22 Sandoz GmbH Brunnleiten 17 A-9300 St. Veit an der Glan Gesellschaft m.b.H., page 25 Biochemiestraße 10 A-3400 Klosterneuburg EUCODIS GmbH, page 26 A-6250 Kundl T. +43/4212/21580 T. +43/2243/326 980 Fibrex Medical Research & Development GmbH, page 27 T. +43/5338/200-0 [email protected] F. +43/2243/257 54 Ionimed Analytik Ges. m.b.H., page 28 F. +43/5338/200-420 [email protected] [email protected] Tiroler Zukunftsstiftung www.vitroplant.at JSW-Research Forschungslabor GmbH, page 29 www.sandoz.at Kaiser-Jäger-Straße 4a Kompetenzzentrum Medizin GmbH, page 30 A-6020 Innsbruck Vogelbusch GmbH Lambda GmbH, page 31 Sandoz GmbH Vienna T. +43/512/576262 Blechturmgasse 11 Mycosafe Diagnostics GmbH, page 18 Wagramer Straße 19 F. +43/512/576262-10 A-1050 Vienna Quantas Analytics GmbH, page 21 A-1220 Vienna [email protected] T. +43/1/546610 Romer Labs Diagnostic GmbH, page 21 T. +43/1/26068 0 www.zukunftsstiftung.at F. +43/1/5452979 Sanochemia Pharmazeutika AG, page 20 F. +43/1/26068 9666 page 15 [email protected] Vienna School of Clinical Research, page 32 [email protected] www.vogelbusch.com vitateq biotechnology GmbH, page 22 www.sandoz.at TissueGnostics GmbH Bioprocessing, page 34 Taborstraße 10/2/8 VTA Engineering u. Umwelttechnik GmbH Sanochemia Pharmazeutica AG A-1020 Vienna BIOPROCESSING Boltzmanngasse 11 Hauptstraße 2 T. +43/1/2161190 A-4675 Weibern ViruSure GmbH, page 33 A-1091 Vienna F. +43/1/2161190 90 T. +43/1/3191456-0 T. +43/7732/41 33 0 Vogelbusch GmbH, page 34 [email protected] F. +43/7732/22 70 F. +43/1/3191456 344 www.tissuegnostics.com [email protected] [email protected] www.vta-umwelttechnik.com SUPPLIERS www.sanochemia.at Topo-Pharma Forschungs- und Produktionsges.m.b.H. Pharmaceuticals, page 20 Biomin GmbH, page 35 Gartengasse 8 VTU-Engineering GmbH Biopure Referenzsubstanzen GmbH, page 21 A-1053 Vienna Parkring 18 Schering Austria GmbH T. +43/1/5451235 0 A-8074 Grambach/Graz CROMA PHARMA GmbH, page 36 Viennaerbergstraße 41 F. +43/1/5451235 4 T. +43/316/4009-200 Quantas Analytics GmbH, page 21 A-1121 Vienna [email protected] F. +43/316/4009-210 Romer Labs Diagnostic GmbH, page 21 T. +43/1/970 37 0 [email protected] vitateq biotechnology GmbH, page 22 F. +43/1/970 37 161 www.vtu.com VTU-Engineering GmbH, page 37 [email protected] Suppliers, page 37 www.schering.at U VTU-Engineering Planungs- und ADVERTISERS SCIOTEC Diagnostic Technologies GmbH ugichem Gesellschaft für organische Chemie mbH Beratungsgesellschaft m.b.H. Human.technology Styria GmbH, page 11 Simmeringer Hauptstraße 24 Mitterweg 24 Parkring 18 A-1110 Vienna A-6020 Innsbruck A-8074 Grambach Life Science Austria (LISA) Vienna Region, page 12 T. +43/1/740 403 61 T. +43/512/282 285 10 40 T. +43/316/4009200 OÖ. Technologie- und Marketinggesellschaft m.b.H., page 13 F. +43/1/740 403 62 F. +43/512/282 285 11 F. +43/316/4009210 Technopol Krems, page 14 [email protected] [email protected] [email protected] Technopol Tulln, page 14 www.sciotec.at www.ugichem.com www.vtu.com Tiroler Zukunftsstiftung, page 15

116/2006 austriantrade.org 41 AUSTRIAEXPORT > INDEXAUSTRIAN TRADE OFFICES ABROAD

ALGERIA CHINA 14, quai Kléber IRELAND 17, Chemin Abdelkader Gaddouche Suite 2280 Beijing Sunflower Tower F-67000 Strasbourg/France Merrion Centre DZ-16035 Hydra – Alger/Algérie No. 37 Maizidian Street Chaoyang District T. +33/3/88 52 29 60 Nutley Lane T. +213/21/69 12 29, 69 27 54 Beijing 100026/The People’s Republic of F. +33/3/88 52 29 61 Dublin 4/Ireland F. +213/21/69 15 90 China [email protected] T. +353/1/283 04 88 [email protected] T. +86/10/85 27 50 50 austriantrade.org/fr F. +353/1/283 05 31 F. +86/10/85 27 50 49 austriantrade.org/dz [email protected] [email protected] GERMANY austriantrade.org/ie ARGENTINA austriantrade.org/cn Stauffenbergstraße 1 Cerrito 1294, piso 15° D-10785 Berlin/Germany ISRAEL C 1010 AAZ Buenos Aires/Argentina Suite 514, West Tower T. +49/30/25 75 75 0 Trade Tower, 9th Floor T. +54/11/48 16 04 79 Shanghai Centre, P.O.Box 155 F. +49/30/25 75 75 75 25, Hamered Street F. +54/11/48 14 36 70 1376 Nanjing Xi Lu [email protected] [email protected] Shanghai 200040/The People’s Republic of austriantrade.org/de Tel Aviv/Israel austriantrade.org/ar China T. +972/3/516 86 85 T. +86/21/62 79 71 97 Unterlindau 21-29 F. +972/3/516 85 80 AUSTRALIA F. +86/21/62 79 71 98 D-60323 Frankfurt am Main/Germany [email protected] 10th floor, 1, York Street [email protected] T. +49/69/97 10 12-0 austriantrade.org/il austriantrade.org/cn Sydney NSW 2000/Australia F. +49/69/97 10 12-29 T. +61/2/92 47 85 81 [email protected] ITALY 13/F, Diamond Exchange Building F. +61/2/92 51 10 38 austriantrade.org/de Piazza del Duomo 20 8-10 Duddell Street, Central [email protected] Hongkong/The People’s Republic of China I-20122 Milano/Italia austriantrade.org/au Promenadeplatz 12/5 T. +39/02/879 09 11 T. +852/25 22 23 88 D-80333 München/Germany F. +39/02/87 73 19 F. +852/28 10 64 93 T. +49/89/24 29 14-0 BELGIUM [email protected] [email protected] F. +49/89/24 29 14-26 479, Avenue Louise, Boîte 52 austriantrade.org/cn austriantrade.org/it B-1050 Bruxelles/Belgique [email protected] austriantrade.org/de T. +32/2/645 16 50 CROATIA Via E. Filiberto, 3 F. +32/2/645 16 69 Ilica 12/2. St. I-35122 Padova/Italia [email protected] GREECE HR-10000 Zagreb/Croatia T. +39/049/876 25 30, austriantrade.org/be Tritis Septemvriou 43 A T. +385/1/488 19 00 GR-104 33 Athen/Greece 876 26 98, 876 27 21 F. +385/1/488 19 12 T. +30/210/884 37 11 T. +39/049/876 27 76 BOSNIA-HERZEGOVINA [email protected] F. +30/210/882 79 13 [email protected] Fra Andjela Zvizdovica 1/19, Tower B austriantrade.org/hr BiH-71000 Sarajevo/Bosnia-Herzegovina [email protected] austriantrade.org/it austriantrade.org/gr T. +387/33/26 78 40, 26 78 50 CZECH REPUBLIC F. +387/33/22 23 36 Krakovská 7 JAPAN HUNGARY [email protected] CZ-111 21 Praha 1/Czech Republic 13-3, 3-Chome, Motoazabu Minato-ku, Délibáb utca 21 austriantrade.org/ba T. +420/222 21 02 55 Tokyo 106-0046/Japan H-1062 Budapest VI/Hungary F. +420/222 21 12 86 T. +81/3/34 03 17 77 T. +36/1/461 50 40 BRAZIL [email protected] F. +81/3/34 03 34 07 F. +36/1/351 12 04 Edificio Network Empresarial austriantrade.org/cz [email protected] [email protected] Av. Dr. Cardoso de Melo, 1340 – conj. 71 austriantrade.org/hu austriantrade.org/jp BR-04548-004 São Paulo – SP/Brazil DENMARK T. +55/11/30 44 99 44 Grønningen 5, III INDIA KOREA F. +55/11/38 42 53 30 DK-1270 København K./Danmark 85, Jor Bagh Kyobo Building, Room 1914 T. +45/33 11 14 12 [email protected] 1-1, Jongno, 1-ga, Jongno-gu F. +45/33 91 14 13 New Delhi 110 003/India austriantrade.org/br Seoul 110-714 /Republic of Korea [email protected] T. +91/11/24 61 83 95, 24 61 83 97, 24 69 17 80-82 T. +82/2/732 73 30, 732 66 49 BULGARIA austriantrade.org/dk F. +91/11/24 61 87 42 F. +82/2/732 43 37 ul. Samuil 35 [email protected] [email protected] BG-1000 Sofia/Bulgaria EGYPT austriantrade.org/in austriantrade.org/kr T. +359/2/953 15 53 8, Ismail Mohamed Street - Zamalek Cairo/Arab Republic of Egypt F. +359/2/953 24 26 INDONESIA isdn +359/2/950 21 25 T. +20/2/735 76 07, 736 11 50, 736 55 63, LIBYA 736 95 09, 735 17 25 Menara Kadin Indonesia, 19th Floor 11-13 Shara el Amir sofi[email protected] Jalan H. R. Rasuna Said Blok X-5, Kav. 2&3 F. +20/2/736 28 92 Abdulkader el Jazairi austriantrade.org/bg Jakarta 12950/Indonesia [email protected] Tripoli/Libya austriantrade.org/eg T. +62/21/25 50 01 86 CANADA F. +62/21/527 47 07 T. +218/21/333 51 76, 333 51 77, 333 04 16 2 Bloor Street West, Suite 400 F. +218/21/333 73 22 EUROPEAN UNION [email protected] Toronto, ON M4W 3E2/Canada [email protected] Avenue de Cortenbergh 30 austriantrade.org/id T. +1/416/967 3348, 967 3380 B-1040 Bruxelles/Belgique austriantrade.org/ly F. +1/416/967 4101 T. +32/2/286 58 80 IRAQ [email protected] F. +32/2/286 58 99 Hay Babil 929 MALAYSIA austriantrade.org/ca [email protected] Street No. 30, House No. 38 Suite 14.1, Level 14, Menara IMC Masbah No. 8, Jalan Sultan Ismail 1010 ouest, rue Sherbrooke, Suite 1410 FINLAND Baghdad/Iraq 50250 Kuala Lumpur/Malaysia Montréal, QC H3A 2R7/Canada Mannerheimintie 15aB sat-T. +87 37 61 35 38 67 T. +60/3/20 32 28 30 T. +1/514/849 3708 FIN-00260 Helsinki/Finland sat-F. +87 37 61 35 38 69 F. +60/3/20 32 31 30 F. +1/514/849 9577 T. +358/9/436 63 30 [email protected] [email protected] [email protected] F. +358/9/43 66 33 99 austriantrade.org/iq austriantrade.org/my austriantrade.org/ca [email protected] austriantrade.org/fi IRAN MOROCCO CHILE Africa Expressway 45, Avenue Hassan II Isidora Goyenechea 2934, FRANCE Golgasht Street 21 Of. 601, Las Condes 6, avenue Pierre 1er de Serbie Teheran/Iran 20000 Casablanca/Maroc Santiago/Chile F-75116 Paris/France T. +98/21/2205 18 20, 2204 77 91, T. +212/22/22 32 82, 22 47 70, T. +56/2/233 05 57 T. +33/1/53 23 05 05 2201 66 28 26 69 04 F. +56/2/233 69 71 F. +33/1/47 20 64 42 F. +98/21/2205 18 16 F. +212/22/22 10 83 [email protected] [email protected] [email protected] [email protected] austriantrade.org/cl austriantrade.org/fr austriantrade.org/ir austriantrade.org/ma

42 austriantrade.org 116/2006 AUSTRIAEXPORT > AUSTRIANAUSTRIA TRADEEXPORT OFFICES ABROAD> INDEX

MEXICO RUSSIA SPAIN Avusturya Dıs, Ticaret Ofisi Avenida Presidente Masaryk 101, 9. Stock Starokonjuschennyi per. 1 Orense, 11-6° Büyükdere Caddesi 100-102 Col. Chapultepec Morales (Polanco) 119 034 Moskau/Russia E-28020 Madrid/España Maya Akar Center B Blok, Floor 14, Office Delegación Miguel Hidalgo T. +7/495/725 63 66 T. +34/91 556 43 58 51 11570 México, D.F./México F. +7/495/230 26 87 F. +34/91 556 99 91 TR-34394 Esentepe – Istanbul/Turkey [email protected] T. +52/55 52 54 44 18, [email protected] T. +90/212/211 14 76 austriantrade.org/ru 55 52 54 44 28, 55 52 54 44 38 austriantrade.org/es F. +90/212/212 01 33 F. +52/55 52 55 16 65 SAUDI ARABIA [email protected] [email protected] Balmes, 200-7°/1 a New Jeddah Chamber of Commerce austriantrade.org/tr austriantrade.org/mx E-08006 Barcelona/España & Industry Building T. +34/93 292 23 78 Al-Ruwais UKRAINE F. +34/93 237 76 21 NETHERLANDS Jeddah 21441/Saudi Arabia wul. Volodimirska, 48 A, 2. Stock Lange Voorhout 58 a [email protected] T. +966/2/651 18 16, 651 23 04 01034 Kiew/Ukraine 2514 EG Den Haag/Nederland austriantrade.org/es F. +966/2/653 37 64 T. +380/44/235 13 41, 235 03 18 T. +31/70/365 49 16 [email protected] F. +380/44/230 25 37 F. +31/70/365 73 21 austriantrade.org/sa SWEDEN [email protected] [email protected] Karlaplan 12 austriantrade.org/ua austriantrade.org/nl Kingdom Tower 23rd Floor SE-11520 Stockholm/Schweden Olaya District, Arouba Road T. +46/8/53 48 88 40 UNITED ARAB EMIRATES NIGERIA Riyadh 11693/Saudi Arabia F. +46/8/660 83 78 Al Khazna Tower, 7th Floor 65A, Oyinkan Abayomi Drive, Ikoyi T. +966/1/211 01 11, 211 01 71, 211 01 77 [email protected] Al Najda Street Lagos/Nigeria F. +966/1/211 02 22 austriantrade.org/se Abu Dhabi/United Arab Emirates T. +234/1/461 35 86, 461 35 87, [email protected] austriantrade.org/sa 269 62 13, 269 04 23, 267 19 55 SWITZERLAND T. +971/2/676 66 33 Talstraße 65, 10 OG F. +234/1/461 35 88 F. +971/2/676 00 02 SERBIA AND MONTENEGRO CH-8001 Zürich/Switzerland [email protected] [email protected] Genex Apartmani, Apt. 103 T. +41/44/215 30 40 austriantrade.org/ng austriantrade.org/ae Vladimira Popovica 6 F. +41/44/212 28 38 CS-11070 Novi Beograd/Srbija i Crna Gora [email protected] UNITED KINGDOM NORWAY T. +381/11/301 58 50 austriantrade.org/ch 45, Princes Gate (Exhibition Road) Oscars gate 81 F. +381/11/311 21 39 N-0256 Oslo/Norge London SW7 2QA/United Kingdom [email protected] SYRIA T. +47/24 11 78 00 austriantrade.org/cs T. +44/20/75 84 44 11 Mezzeh, Eastern Villas F. +47/24 11 78 01 F. +44/20/75 84 25 65 Farabi Street 116a [email protected] SINGAPORE [email protected] Damascus/Syria austriantrade.org/no 600 North Bridge Road austriantrade.org/uk T. +963/11/611 77 71, 611 46 16 #24-04/05 Parkview Square F. +963/11/613 20 78 PHILIPPINES Singapore 188778/Rep. of Singapore USA [email protected] 14th Floor, The Pacific Star Bldg. T. +65/63 96 63 50, 63 96 63 51, 120 West 45th Street, 9th Floor 63 96 63 52 austriantrade.org/sy Sen. Gil J. Puyat Ave./Corner Makati Ave. New York, NY 10036/USA F. +65/63 96 63 40 1200 Makati City, Metro Manila/Philippines T. +1/212/421-5250 [email protected] TAIWAN T. +63/2/818 15 81 F. +1/212/421-5251 austriantrade.org/sg Bank Tower, Suite 608 F. +63/2/810 37 13 Dunhua N. Rd. 205 [email protected] [email protected] SLOVAKIA Taipei 105/Taiwan austriantrade.org/us austriantrade.org/ph Europeum Business Centre T. +886/2/27 15 52 20 Suché my’to 1, Stiege A, 3. Stock F. +886/2/27 17 32 42 500 North Michigan Avenue, Suite 1950 POLAND SK-811 03 Bratislava/Slovensko [email protected] Chicago, IL 60611-3722/USA Saski Cresent Center, ul. Królewska 16, T. +421/2/59 100 600 austriantrade.org/tw T. +1/312/644-5556 PL-00-103 Warszawa/Poland F. +421/2/59 100 699 F. +1/312/644-6526 T. +48/22/586 44 66 [email protected] THAILAND [email protected] F. +48/22/586 44 88 austriantrade.org/sk Chartered Square Building, 14th Floor, austriantrade.org/us [email protected] Suite 1403 austriantrade.org/pl SLOVENIA 152 North Sathorn Road 11601 Wilshire Blvd., Suite 2420 Nazorjeva 6 Bangkok 10500/Thailand Postni predal 1595 Los Angeles, CA 90025/USA PORTUGAL T. +66/2/268 22 22 SI-1000 Ljubljana/Slovenija T. +1/310/477-9988 Rua Rodrigues Sampaio, 18-5° F. +66/2/200 02 22 T. +386/1/513 97 70 F. +1/310/477-1643 P-1169-027 Lisboa/Portugal [email protected] F. +386/1/513 97 80 [email protected] T. +351/213 17 10 10 austriantrade.org/th [email protected] F. +351/213 17 10 18 austriantrade.org/us austriantrade.org/si [email protected] TURKEY VENEZUELA austriantrade.org/pt Armada Business Center SOUTH AFRICA Edificio Plaza C/PH Cradock Heights, 2nd Floor Eskisehir Yolu 6, Calle Londres entre Caroni y Nueva York ROMANIA 21 Cradock Avenue (Corner Tyrwhitt Avenue) Floor 13, Office 19 Las Mercedes Strada Logofat Luca Stroici Nr. 15 Rosebank (Johannesburg)/Rep. of South 06520 Sögütözü RO-020581 Bucuresti/Romania Africa Ankara, Turkey Caracas/Venezuela T. +40/21/210 17 98, 210 17 99 T. +27/11/442 71 00 T. +90/312/219 21 41 (PBX) T. +58/212/993 98 44 F. +40/21/210 23 99 F. +27/11/442 83 04 F. +90/312/219 21 45 F. +58/212/993 99 35 [email protected] [email protected] [email protected] [email protected] austriantrade.org/ro austriantrade.org/za austriantrade.org/tr austriantrade.org/ve

116/2006 austriantrade.org 43 CPG

IHR OUTSOURCING-PARTNER

Harte Zeiten brauchen neue Ideen: Die CPG verleiht Ihrem Umsatz mit maßgeschneiderter Kommunikation Flügel. Mit Magazinen, Magalogen, Zeitschriften und Broschüren, die Mitarbeiter motivieren, Endverbraucher informieren und Geschäftspartner von Ihnen und Ihren Produkten überzeugen. Weltweit, mit den besten Partnern vor Ort. CPG – Ihr Partner von Welt.

Referenzen I Abbott Diagnostica I Außenwirtschaft/Wirtschaftskammer Österreich I Biotherm I Capital Bank I Designbau I Golfclub Leopoldsdorf I Inode I M&A PrivatBank I Nestlé I Novomatic I ÖSW I Peugeot I Post & Telekom Immobilien I Schwabe, Ley & Greiner I Seat I UTA I zBp I ZEPRA … und wann entscheiden Sie sich für die CPG?

CPG I Corporate Publishing Group, Strozzigasse 10/EG, A-1080 Wien I Tel.: + 43 1 4054640-763 I E-Mail: [email protected]